{"data": [{"entities": {"mentions": [{"start": 0, "end": 14, "username": "celinegounder", "id": "58006725"}, {"start": 15, "end": 25, "username": "GrantWahl", "id": "36623013"}]}, "text": "@celinegounder @GrantWahl So sorry. Heartbreaking news.", "source": "Twitter for iPhone", "created_at": "2022-12-10T04:06:03.000Z", "edit_history_tweet_ids": ["1601428002617061376"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601404727014879232"}], "id": "1601428002617061376", "in_reply_to_user_id": "58006725", "conversation_id": "1601404727014879232"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 29, "end": 41, "username": "JatinShahMD", "id": "221642631"}, {"start": 42, "end": 57, "username": "ASH_hematology", "id": "84072624"}, {"start": 199, "end": 214, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 219, "end": 231, "username": "JatinShahMD", "id": "221642631"}]}, "text": "@chadinabhan @AaronGoodman33 @JatinShahMD @ASH_hematology Thanks for this meeting a Chadi. A real pleasure to meet with trainees seeking a career in academic medicine. Wonderful to meet up with you, @AaronGoodman33 and @JatinShahMD", "source": "Twitter for iPhone", "created_at": "2022-12-10T03:45:25.000Z", "edit_history_tweet_ids": ["1601422808176680960"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601409465948872704"}], "id": "1601422808176680960", "in_reply_to_user_id": "2212735524", "conversation_id": "1601409465948872704"}, {"entities": {"mentions": [{"start": 3, "end": 15, "username": "chadinabhan", "id": "2212735524"}, {"start": 31, "end": 46, "username": "ASH_hematology", "id": "84072624"}, {"start": 59, "end": 74, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 81, "end": 91, "username": "VincentRK", "id": "24261916"}], "hashtags": [{"start": 47, "end": 53, "tag": "ASH22"}]}, "text": "RT @chadinabhan: Right here at @ASH_hematology #ASH22 with @AaronGoodman33 &amp; @VincentRK discussing science, mentorship, and music. \n\nGreat\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-10T03:38:03.000Z", "edit_history_tweet_ids": ["1601420956353691648"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1601400573555019776"}], "id": "1601420956353691648", "conversation_id": "1601420956353691648"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 26, "username": "DianaGHealth", "id": "218351292"}, {"start": 27, "end": 39, "username": "drkomanduri", "id": "1081903728"}]}, "text": "@chadinabhan @DianaGHealth @drkomanduri I\u2019m meeting you today! In like a minute.", "source": "Twitter for iPhone", "created_at": "2022-12-10T00:38:01.000Z", "edit_history_tweet_ids": ["1601375647477420032"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601372875193081856"}], "id": "1601375647477420032", "in_reply_to_user_id": "2212735524", "conversation_id": "1601361416644362240"}, {"text": "Have something on MGUS soon. Stay tuned.", "source": "Twitter for iPhone", "created_at": "2022-12-10T00:36:48.000Z", "edit_history_tweet_ids": ["1601375341318397952"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601375218513375232"}], "id": "1601375341318397952", "in_reply_to_user_id": "24261916", "conversation_id": "1601372628232851456"}, {"text": "Except for slight modifications expanding  DRd options in frontline after discussion with colleagues on the panel today, this is essentially same as what I posted a few days ago.", "source": "Twitter for iPhone", "created_at": "2022-12-10T00:36:18.000Z", "edit_history_tweet_ids": ["1601375218513375232"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601372656707649536"}], "id": "1601375218513375232", "in_reply_to_user_id": "24261916", "conversation_id": "1601372628232851456"}, {"text": "5. Smoldering myeloma. For the one third who meet criteria for high risk smoldering myeloma, recommend therapy with  Len or Len/Dex for 2 years or clinical trial. #ASH22 https://t.co/XUKxCngyT6", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 14, "end": 20, "probability": 0.5789, "type": "Other", "normalized_text": "myeloma"}, {"start": 84, "end": 90, "probability": 0.5639, "type": "Other", "normalized_text": "myeloma"}, {"start": 117, "end": 119, "probability": 0.7411, "type": "Other", "normalized_text": "Len"}, {"start": 124, "end": 126, "probability": 0.7029, "type": "Other", "normalized_text": "Len"}, {"start": 128, "end": 130, "probability": 0.5914, "type": "Other", "normalized_text": "Dex"}, {"start": 164, "end": 168, "probability": 0.4756, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 170, "end": 193, "url": "https://t.co/XUKxCngyT6", "expanded_url": "https://twitter.com/VincentRK/status/1601372656707649536/photo/1", "display_url": "pic.twitter.com/XUKxCngyT6", "media_key": "3_1601372651989213189"}], "hashtags": [{"start": 163, "end": 169, "tag": "ASH22"}]}, "created_at": "2022-12-10T00:26:08.000Z", "edit_history_tweet_ids": ["1601372656707649536"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601372649598648320"}], "id": "1601372656707649536", "in_reply_to_user_id": "24261916", "conversation_id": "1601372628232851456"}, {"text": "4. Second on higher  relapse. Try one of the first relapse regimens that the patient is not refractory to. #ASH22 \n\nTriple refractory: Either alkylator or BCMA targeted therapy. \n\nBCMA refractory options also listed below. https://t.co/3dfjHxAQha", "source": "Twitter for iPhone", "entities": {"urls": [{"start": 223, "end": 246, "url": "https://t.co/3dfjHxAQha", "expanded_url": "https://twitter.com/VincentRK/status/1601372649598648320/photo/1", "display_url": "pic.twitter.com/3dfjHxAQha", "media_key": "3_1601372645341253633"}], "hashtags": [{"start": 107, "end": 113, "tag": "ASH22"}]}, "created_at": "2022-12-10T00:26:06.000Z", "edit_history_tweet_ids": ["1601372649598648320"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601372642866761728"}], "id": "1601372649598648320", "in_reply_to_user_id": "24261916", "conversation_id": "1601372628232851456"}, {"text": "3. First relapse. The approach depends on refractoriness to Len and CD38moAB. For CD38 Moab either Daratumumab or Isatuximab are OK. Depends on cost and availability. #ASH22 https://t.co/Nw0afMaOxF", "source": "Twitter for iPhone", "entities": {"urls": [{"start": 174, "end": 197, "url": "https://t.co/Nw0afMaOxF", "expanded_url": "https://twitter.com/VincentRK/status/1601372642866761728/photo/1", "display_url": "pic.twitter.com/Nw0afMaOxF", "media_key": "3_1601372639175524353"}], "hashtags": [{"start": 167, "end": 173, "tag": "ASH22"}]}, "created_at": "2022-12-10T00:26:04.000Z", "edit_history_tweet_ids": ["1601372642866761728"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601372636268765187"}], "id": "1601372642866761728", "in_reply_to_user_id": "24261916", "conversation_id": "1601372628232851456"}, {"text": "2. Newly Diagnosed myeloma transplant eligible. #ASH22\n\nEarly transplant preferred. But for selected standard risk patients depending on preference, delayed is also OK. Maintenance varies by risk stratification. https://t.co/pfV83LhB5R", "source": "Twitter for iPhone", "entities": {"urls": [{"start": 212, "end": 235, "url": "https://t.co/pfV83LhB5R", "expanded_url": "https://twitter.com/VincentRK/status/1601372636268765187/photo/1", "display_url": "pic.twitter.com/pfV83LhB5R", "media_key": "3_1601372631135035395"}], "hashtags": [{"start": 48, "end": 54, "tag": "ASH22"}]}, "created_at": "2022-12-10T00:26:03.000Z", "edit_history_tweet_ids": ["1601372636268765187"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601372628232851456"}], "id": "1601372636268765187", "in_reply_to_user_id": "24261916", "conversation_id": "1601372628232851456"}, {"entities": {"mentions": [{"start": 50, "end": 61, "username": "IMFmyeloma", "id": "34340707"}, {"start": 62, "end": 76, "username": "CCO_Education", "id": "262835058"}], "annotations": [{"start": 8, "end": 14, "probability": 0.6613, "type": "Other", "normalized_text": "Myeloma"}, {"start": 26, "end": 35, "probability": 0.4109, "type": "Other", "normalized_text": "Algorithms"}, {"start": 98, "end": 102, "probability": 0.5436, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 216, "end": 239, "url": "https://t.co/GlniXt6h5q", "expanded_url": "https://twitter.com/VincentRK/status/1601372628232851456/photo/1", "display_url": "pic.twitter.com/GlniXt6h5q", "media_key": "3_1601372624642351109"}], "hashtags": [{"start": 97, "end": 103, "tag": "ASH22"}]}, "text": "Updated Myeloma Treatment Algorithms presented at @IMFmyeloma @CCO_Education symposium  today at #ASH22 \n\n1. Newly diagnosed transplant ineligible. Either VRd or DRd is OK. Maintenance varies by risk stratification. https://t.co/GlniXt6h5q", "source": "Twitter for iPhone", "created_at": "2022-12-10T00:26:01.000Z", "edit_history_tweet_ids": ["1601372628232851456"], "author_id": "24261916", "lang": "en", "id": "1601372628232851456", "conversation_id": "1601372628232851456"}, {"entities": {"mentions": [{"start": 0, "end": 13, "username": "DianaGHealth", "id": "218351292"}, {"start": 14, "end": 26, "username": "drkomanduri", "id": "1081903728"}]}, "text": "@DianaGHealth @drkomanduri Sure.", "source": "Twitter for iPhone", "created_at": "2022-12-09T23:53:46.000Z", "edit_history_tweet_ids": ["1601364514083307520"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601364427093123072"}], "id": "1601364514083307520", "in_reply_to_user_id": "218351292", "conversation_id": "1601361416644362240"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "drkomanduri", "id": "1081903728"}]}, "text": "@drkomanduri Same. Let\u2019s meet up tomorrow.", "source": "Twitter for iPhone", "created_at": "2022-12-09T23:53:04.000Z", "edit_history_tweet_ids": ["1601364335951237122"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601362946294435841"}], "id": "1601364335951237122", "in_reply_to_user_id": "1081903728", "conversation_id": "1601361416644362240"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "drkomanduri", "id": "1081903728"}]}, "text": "@drkomanduri We should meet.", "source": "Twitter for iPhone", "created_at": "2022-12-09T23:45:38.000Z", "edit_history_tweet_ids": ["1601362468395094016"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601361416644362240"}], "id": "1601362468395094016", "in_reply_to_user_id": "1081903728", "conversation_id": "1601361416644362240"}, {"entities": {"mentions": [{"start": 0, "end": 13, "username": "MaryTheobald", "id": "363459113"}, {"start": 14, "end": 29, "username": "SandyWong02111", "id": "4050824739"}, {"start": 30, "end": 41, "username": "ninashah33", "id": "1559241414"}, {"start": 42, "end": 58, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 59, "end": 69, "username": "TomBmt133", "id": "812851718014701568"}]}, "text": "@MaryTheobald @SandyWong02111 @ninashah33 @RahulBanerjeeMD @TomBmt133 In myeloma median time to progression after CART is 12-24 months. We hope it\u2019s much longer if we can move it earlier in the disease course.", "source": "Twitter for iPhone", "created_at": "2022-12-09T23:44:58.000Z", "edit_history_tweet_ids": ["1601362300048330752"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601360246077022208"}], "id": "1601362300048330752", "in_reply_to_user_id": "363459113", "conversation_id": "1601235882824331267"}, {"text": "Catching up with Jesus SanMiguel at #ASH22\n\nWe have worked together on so many initiatives in myeloma. I\u2019m always amazed at his thoughtfulness and wisdom. https://t.co/eei0nyC6Id", "source": "Twitter for iPhone", "entities": {"urls": [{"start": 155, "end": 178, "url": "https://t.co/eei0nyC6Id", "expanded_url": "https://twitter.com/VincentRK/status/1601361899337052160/photo/1", "display_url": "pic.twitter.com/eei0nyC6Id", "media_key": "3_1601361890499764225"}], "hashtags": [{"start": 36, "end": 42, "tag": "ASH22"}]}, "created_at": "2022-12-09T23:43:23.000Z", "edit_history_tweet_ids": ["1601361899337052160"], "author_id": "24261916", "lang": "en", "id": "1601361899337052160", "conversation_id": "1601361899337052160"}, {"entities": {"mentions": [{"start": 3, "end": 14, "username": "NorthTxMSG", "id": "961409220"}, {"start": 20, "end": 30, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 47, "end": 50, "probability": 0.6636, "type": "Other", "normalized_text": "TRAP"}, {"start": 96, "end": 100, "probability": 0.6242, "type": "Other", "normalized_text": "ASH22"}, {"start": 103, "end": 106, "probability": 0.6143, "type": "Other", "normalized_text": "mmsm"}], "hashtags": [{"start": 95, "end": 101, "tag": "ASH22"}, {"start": 102, "end": 107, "tag": "mmsm"}]}, "text": "RT @NorthTxMSG: Dr. @VincentRK introducing his TRAP treatment selection acronym as part of his #ASH22 #mmsm treatment algorithm. https://t.\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-09T18:59:26.000Z", "edit_history_tweet_ids": ["1601290441147944962"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1601287835507490817"}], "id": "1601290441147944962", "conversation_id": "1601290441147944962"}, {"entities": {"mentions": [{"start": 3, "end": 13, "username": "myelomaMD", "id": "301568235"}, {"start": 74, "end": 88, "username": "CCO_Education", "id": "262835058"}, {"start": 91, "end": 102, "username": "IMFmyeloma", "id": "34340707"}, {"start": 123, "end": 133, "username": "myelomaMD", "id": "301568235"}], "annotations": [{"start": 38, "end": 42, "probability": 0.5014, "type": "Other", "normalized_text": "ASH22"}, {"start": 64, "end": 70, "probability": 0.7146, "type": "Other", "normalized_text": "myeloma"}, {"start": 99, "end": 111, "probability": 0.9326, "type": "Person", "normalized_text": "oma\u2069 \nPhilipp"}], "hashtags": [{"start": 37, "end": 43, "tag": "ASH22"}]}, "text": "RT @myelomaMD: We are about to start #ASH22 Friday symposium on myeloma. \u2066@CCO_Education\u2069 \u2066@IMFmyeloma\u2069 \nPhilippe Moreau, \u2066@myelomaMD\u2069 \u2066@Yi\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-09T17:25:26.000Z", "edit_history_tweet_ids": ["1601266784828432386"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1601263313320542209"}], "id": "1601266784828432386", "conversation_id": "1601266784828432386"}, {"entities": {"mentions": [{"start": 3, "end": 13, "username": "VincentRK", "id": "24261916"}, {"start": 38, "end": 48, "username": "myelomaMD", "id": "301568235"}], "hashtags": [{"start": 18, "end": 24, "tag": "ASH22"}]}, "text": "RT @VincentRK: At #ASH22 my colleague @myelomaMD will present the initial results of the ASCENT trial, aka the 2nd Cure trial to test the h\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-09T15:57:38.000Z", "edit_history_tweet_ids": ["1601244691126972417"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600900413330374657"}], "id": "1601244691126972417", "conversation_id": "1601244691126972417"}, {"entities": {"mentions": [{"start": 122, "end": 132, "username": "TomBmt133", "id": "812851718014701568"}]}, "text": "Interestingly some treatments that previously stopped working like CD38 Moab, Imids, PIs showed some effect post CAR-T. \n\n@TomBmt133 - what did you think?", "source": "Twitter for iPhone", "created_at": "2022-12-09T15:23:48.000Z", "edit_history_tweet_ids": ["1601236173841584129"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601235886477545472"}], "id": "1601236173841584129", "in_reply_to_user_id": "24261916", "conversation_id": "1601235882824331267"}, {"text": "Probably also in part reflects the patient selection for CAR-T. #ASH22", "source": "Twitter for iPhone", "created_at": "2022-12-09T15:22:39.000Z", "edit_history_tweet_ids": ["1601235886477545472"], "author_id": "24261916", "lang": "en", "entities": {"hashtags": [{"start": 64, "end": 70, "tag": "ASH22"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1601235882824331267"}], "id": "1601235886477545472", "in_reply_to_user_id": "24261916", "conversation_id": "1601235882824331267"}, {"entities": {"mentions": [{"start": 179, "end": 194, "username": "SandyWong02111", "id": "4050824739"}, {"start": 195, "end": 206, "username": "ninashah33", "id": "1559241414"}, {"start": 207, "end": 223, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 224, "end": 234, "username": "TomBmt133", "id": "812851718014701568"}], "annotations": [{"start": 11, "end": 15, "probability": 0.5514, "type": "Other", "normalized_text": "CAR-T"}, {"start": 20, "end": 26, "probability": 0.6062, "type": "Other", "normalized_text": "myeloma"}, {"start": 30, "end": 34, "probability": 0.5962, "type": "Other", "normalized_text": "ASH22"}, {"start": 101, "end": 105, "probability": 0.6813, "type": "Other", "normalized_text": "CAR-T"}, {"start": 168, "end": 177, "probability": 0.7291, "type": "Person", "normalized_text": "KevinReyes"}], "urls": [{"start": 235, "end": 258, "url": "https://t.co/IxU6jcxOGH", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper160401.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy", "description": "Progra m: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Relapsed and/or Refractory Myeloma (RRMM) Hematology Disease Topics & Pathways: Research, Biological therapies, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Clinical Research, health outcomes research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Immunotherapy, therapy sequence, Lymphoid", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper160401.html"}, {"start": 259, "end": 282, "url": "https://t.co/tHEheouRHm", "expanded_url": "https://twitter.com/VincentRK/status/1601235882824331267/photo/1", "display_url": "pic.twitter.com/tHEheouRHm", "media_key": "3_1601235876239097856"}], "hashtags": [{"start": 29, "end": 35, "tag": "ASH22"}, {"start": 167, "end": 178, "tag": "KevinReyes"}]}, "text": "Life after CAR-T in myeloma. #ASH22 abstract shows median survival of 15 months after progression on CAR-T. \n\nIndicates that we have options for therapy post CAR-T. \n\n#KevinReyes @SandyWong02111 @ninashah33 @RahulBanerjeeMD @TomBmt133 https://t.co/IxU6jcxOGH https://t.co/tHEheouRHm", "source": "Twitter for iPhone", "created_at": "2022-12-09T15:22:38.000Z", "edit_history_tweet_ids": ["1601235882824331267"], "author_id": "24261916", "lang": "en", "id": "1601235882824331267", "conversation_id": "1601235882824331267"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "CCO_Education", "id": "262835058"}], "hashtags": [{"start": 191, "end": 197, "tag": "ASH22"}]}, "text": "@CCO_Education Jesus San Miguel will cover SMM\n\nPhilippe Moreau - Newly Diagnosed Myeloma and Transplant. \n\nShaji Kumar, Yi Lin, Tom Martin - Relapsed Myeloma including bispecifics and CART. #ASH22", "source": "Twitter for iPhone", "created_at": "2022-12-09T15:10:30.000Z", "edit_history_tweet_ids": ["1601232827755819008"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601231076378148866"}], "id": "1601232827755819008", "in_reply_to_user_id": "262835058", "conversation_id": "1601231076378148866"}, {"entities": {"mentions": [{"start": 3, "end": 17, "username": "CCO_Education", "id": "262835058"}], "hashtags": [{"start": 32, "end": 40, "tag": "ASH2022"}]}, "text": "RT @CCO_Education: 11AM CT Pre- #ASH2022 Friday Session Reminder! Myeloma: Evolving Treatment Landscape, with IMF @ HYATT REGENCY in ELITE\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-09T15:05:59.000Z", "edit_history_tweet_ids": ["1601231693381525504"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1601231076378148866"}], "id": "1601231693381525504", "conversation_id": "1601231693381525504"}, {"entities": {"mentions": [{"start": 186, "end": 200, "username": "CCO_Education", "id": "262835058"}, {"start": 201, "end": 212, "username": "IMFmyeloma", "id": "34340707"}], "hashtags": [{"start": 172, "end": 178, "tag": "ASH22"}]}, "text": "When should we start treatment at relapse in myeloma: \n-Clinical progression? -Significant paraprotein increase? \n-Relapse from CR or MRD- ?\n\nI will be discussing today at #ASH22 Friday @CCO_Education @IMFmyeloma symposium \u2014 11AM Hyatt Regency.", "source": "Twitter for iPhone", "created_at": "2022-12-09T14:42:49.000Z", "edit_history_tweet_ids": ["1601225862702956545"], "author_id": "24261916", "lang": "en", "id": "1601225862702956545", "conversation_id": "1601225862702956545"}, {"entities": {"mentions": [{"start": 3, "end": 13, "username": "majorajay", "id": "409755591"}, {"start": 50, "end": 60, "username": "VincentRK", "id": "24261916"}, {"start": 61, "end": 71, "username": "myelomaMD", "id": "301568235"}], "hashtags": [{"start": 26, "end": 32, "tag": "ASH22"}]}, "text": "RT @majorajay: Phenomenal #ASH22 abstract by Drs. @VincentRK @myelomaMD et al. on a question I got every week as a myeloma fellow by patien\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-09T14:29:44.000Z", "edit_history_tweet_ids": ["1601222571449778176"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600930651233931264"}], "id": "1601222571449778176", "conversation_id": "1601222571449778176"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "MunshiNc", "id": "1600232317343203329"}], "annotations": [{"start": 16, "end": 21, "probability": 0.7298, "type": "Other", "normalized_text": "Nikhil"}, {"start": 49, "end": 55, "probability": 0.9503, "type": "Other", "normalized_text": "Twitter"}]}, "text": "@MunshiNc Great Nikhil! Welcome. Glad you are on Twitter.", "source": "Twitter for iPhone", "created_at": "2022-12-09T03:28:14.000Z", "edit_history_tweet_ids": ["1601056096051171329"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601055876286058496"}], "id": "1601056096051171329", "in_reply_to_user_id": "1600232317343203329", "conversation_id": "1601055876286058496"}, {"entities": {"mentions": [{"start": 3, "end": 12, "username": "MunshiNc", "id": "1600232317343203329"}, {"start": 82, "end": 92, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 18, "end": 22, "probability": 0.5822, "type": "Other", "normalized_text": "ASH22"}, {"start": 65, "end": 76, "probability": 0.9472, "type": "Person", "normalized_text": "Ken Anderson"}], "urls": [{"start": 93, "end": 116, "url": "https://t.co/rAmJkei5QW", "expanded_url": "https://twitter.com/MunshiNc/status/1601055876286058496/photo/1", "display_url": "pic.twitter.com/rAmJkei5QW", "media_key": "3_1601055869348843523"}], "hashtags": [{"start": 17, "end": 23, "tag": "ASH22"}]}, "text": "RT @MunshiNc: At #ASH22. MY first tweet with my 2 best friends ! Ken Anderson and @VincentRK https://t.co/rAmJkei5QW", "source": "Twitter for iPhone", "created_at": "2022-12-09T03:27:36.000Z", "edit_history_tweet_ids": ["1601055939175804930"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1601055876286058496"}], "id": "1601055939175804930", "conversation_id": "1601055939175804930"}, {"text": "Mmm. Interesting. https://t.co/ee6KYYvtIU", "source": "Twitter for iPhone", "entities": {"urls": [{"start": 18, "end": 41, "url": "https://t.co/ee6KYYvtIU", "expanded_url": "https://twitter.com/VincentRK/status/1600851323590680577", "display_url": "twitter.com/VincentRK/stat\u2026"}]}, "created_at": "2022-12-09T01:49:52.000Z", "edit_history_tweet_ids": ["1601031343185440768"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600851323590680577"}], "id": "1601031343185440768", "conversation_id": "1601031343185440768"}, {"entities": {"mentions": [{"start": 3, "end": 19, "username": "DrMiguelPerales", "id": "1407780158"}, {"start": 28, "end": 38, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 22, "end": 26, "probability": 0.5126, "type": "Other", "normalized_text": "ASH22"}, {"start": 63, "end": 73, "probability": 0.5197, "type": "Other", "normalized_text": "Elranatamab"}], "hashtags": [{"start": 21, "end": 27, "tag": "ASH22"}]}, "text": "RT @DrMiguelPerales: #ASH22 @VincentRK Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022 https://t.co/c2v8\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-09T01:27:11.000Z", "edit_history_tweet_ids": ["1601025634020384768"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600973804129648642"}], "id": "1601025634020384768", "conversation_id": "1601025634020384768"}, {"entities": {"mentions": [{"start": 3, "end": 9, "username": "fibke", "id": "237899667"}]}, "text": "RT @fibke: The global vax campaign is far more unequal today than it was earlier in the pandemic. \n\nBooster momentum is close to 0 in devel\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-08T21:42:43.000Z", "edit_history_tweet_ids": ["1600969145507803136"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600394509623386112"}], "id": "1600969145507803136", "conversation_id": "1600969145507803136"}, {"entities": {"mentions": [{"start": 3, "end": 11, "username": "OncLive", "id": "43051682"}, {"start": 105, "end": 115, "username": "VincentRK", "id": "24261916"}, {"start": 116, "end": 131, "username": "MayoCancerCare", "id": "2396756364"}], "annotations": [{"start": 13, "end": 20, "probability": 0.6243, "type": "Person", "normalized_text": "Rajkumar"}, {"start": 46, "end": 56, "probability": 0.5449, "type": "Other", "normalized_text": "Elranatamab"}]}, "text": "RT @OncLive: Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022 @VincentRK @MayoCancerCare @ASH_he\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-08T21:20:15.000Z", "edit_history_tweet_ids": ["1600963491220713472"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600948429877907456"}], "id": "1600963491220713472", "conversation_id": "1600963491220713472"}, {"text": "My thoughts on SMM were shaped and influenced years ago through conversations with Drs. Kyle, San Miguel, Merlini, Landgren, Mateos, Lonial, Kumar, Durie, Paiva, Dimopoulos, and many others. \n\nSo glad to see continued progress.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 15, "end": 17, "probability": 0.5437, "type": "Other", "normalized_text": "SMM"}, {"start": 83, "end": 85, "probability": 0.348, "type": "Person", "normalized_text": "Drs"}, {"start": 88, "end": 91, "probability": 0.4766, "type": "Person", "normalized_text": "Kyle"}, {"start": 94, "end": 103, "probability": 0.4733, "type": "Person", "normalized_text": "San Miguel"}, {"start": 106, "end": 112, "probability": 0.4719, "type": "Other", "normalized_text": "Merlini"}, {"start": 115, "end": 122, "probability": 0.5189, "type": "Person", "normalized_text": "Landgren"}, {"start": 125, "end": 130, "probability": 0.5211, "type": "Person", "normalized_text": "Mateos"}, {"start": 133, "end": 138, "probability": 0.478, "type": "Person", "normalized_text": "Lonial"}, {"start": 141, "end": 145, "probability": 0.5884, "type": "Person", "normalized_text": "Kumar"}, {"start": 148, "end": 152, "probability": 0.4671, "type": "Other", "normalized_text": "Durie"}, {"start": 155, "end": 159, "probability": 0.5872, "type": "Person", "normalized_text": "Paiva"}, {"start": 162, "end": 171, "probability": 0.4899, "type": "Other", "normalized_text": "Dimopoulos"}]}, "created_at": "2022-12-08T17:50:34.000Z", "edit_history_tweet_ids": ["1600910723974311937"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600910040931520512"}], "id": "1600910723974311937", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"entities": {"mentions": [{"start": 166, "end": 180, "username": "IreneGhobrial", "id": "452461489"}, {"start": 185, "end": 199, "username": "DrOlaLandgren", "id": "2257190339"}], "annotations": [{"start": 90, "end": 92, "probability": 0.6869, "type": "Other", "normalized_text": "SMM"}]}, "text": "I must say many leaders in the field share the same vision and commitment with regards to SMM. And are doing a range of studies and trials in this regard, especially @IreneGhobrial and @DrOlaLandgren \n\nThe full spectrum of studies is what it will take to solve this puzzle.", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:47:51.000Z", "edit_history_tweet_ids": ["1600910040931520512"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600904751147003904"}], "id": "1600910040931520512", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "barttels2", "id": "3497730012"}, {"start": 11, "end": 24, "username": "DeVitaDoctor", "id": "50178358"}]}, "text": "@barttels2 @DeVitaDoctor Agree.  And same for me.  Amazing book. Strongly recommend to all oncologists.", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:43:02.000Z", "edit_history_tweet_ids": ["1600908825804300288"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600908510178738177"}], "id": "1600908825804300288", "in_reply_to_user_id": "3497730012", "conversation_id": "1600900413330374657"}, {"entities": {"mentions": [{"start": 8, "end": 17, "username": "MunshiNc", "id": "1600232317343203329"}, {"start": 193, "end": 204, "username": "DanaFarber", "id": "15282064"}, {"start": 205, "end": 216, "username": "harvardmed", "id": "30862829"}], "annotations": [{"start": 24, "end": 30, "probability": 0.926, "type": "Other", "normalized_text": "Twitter"}, {"start": 97, "end": 109, "probability": 0.4975, "type": "Other", "normalized_text": "Nikhil Munshi"}, {"start": 149, "end": 163, "probability": 0.4027, "type": "Other", "normalized_text": "Myeloma Society"}, {"start": 174, "end": 178, "probability": 0.4439, "type": "Other", "normalized_text": "Kraft"}], "hashtags": [{"start": 84, "end": 90, "tag": "ASH22"}]}, "text": "Finally @MunshiNc is on Twitter! Follow him if interested in hematology or myeloma. #ASH22 \n\nDr. Nikhil Munshi is the President of the International Myeloma Society, and the Kraft Family Chair @DanaFarber @harvardmed", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:37:35.000Z", "edit_history_tweet_ids": ["1600907457458765825"], "author_id": "24261916", "lang": "en", "id": "1600907457458765825", "conversation_id": "1600907457458765825"}, {"entities": {"mentions": [{"start": 60, "end": 73, "username": "DeVitaDoctor", "id": "50178358"}], "annotations": [{"start": 104, "end": 119, "probability": 0.7154, "type": "Other", "normalized_text": "Hodgkin lymphoma"}]}, "text": "We have the same vision and goal. For me it was inspired by @DeVitaDoctor and how he approached cure in Hodgkin lymphoma: Cure means fixed duration therapy, stop treatment, the disease never ever comes back in a reasonable proportion of patients.  \n\nThat\u2019s what we are going for.", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:26:50.000Z", "edit_history_tweet_ids": ["1600904751147003904"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600903774326833153"}], "id": "1600904751147003904", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"entities": {"mentions": [{"start": 3, "end": 15, "username": "chadinabhan", "id": "2212735524"}], "annotations": [{"start": 82, "end": 84, "probability": 0.7944, "type": "Other", "normalized_text": "MRD"}]}, "text": "RT @chadinabhan: I love the fact that this is a fixed duration study and explores MRD. I believe curing a disease requires eradication at t\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:24:43.000Z", "edit_history_tweet_ids": ["1600904218155528194"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600901994658418688"}], "id": "1600904218155528194", "conversation_id": "1600904218155528194"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 28, "username": "ASH_hematology", "id": "84072624"}]}, "text": "@chadinabhan @ASH_hematology Yes. Cure means fixed duration therapy, stop treatment, the disease never ever comes back in a reasonable proportion of patients.  \n\nThat\u2019s what we are going for.", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:24:42.000Z", "edit_history_tweet_ids": ["1600904213080707073"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600901994658418688"}], "id": "1600904213080707073", "in_reply_to_user_id": "2212735524", "conversation_id": "1600901994658418688"}, {"entities": {"mentions": [{"start": 118, "end": 127, "username": "mvmateos", "id": "2239926566"}, {"start": 132, "end": 142, "username": "myelomaMD", "id": "301568235"}]}, "text": "This is a multi decade vision. I\u2019m glad the trials were started and we already have years of follow up. \n\nCongrats to @mvmateos and @myelomaMD for overcoming numerous obstacles to get us to this point.", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:22:57.000Z", "edit_history_tweet_ids": ["1600903774326833153"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600903255004831744"}], "id": "1600903774326833153", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"text": "There will be successor trials similar to CESAR and ASCENT. If and when the results look very promising the next step would be to compare the winning regimen from one of the Cure trials to whatever is standard of care at the time in a randomized trial.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 42, "end": 46, "probability": 0.3215, "type": "Person", "normalized_text": "CESAR"}, {"start": 52, "end": 57, "probability": 0.5336, "type": "Other", "normalized_text": "ASCENT"}]}, "created_at": "2022-12-08T17:20:53.000Z", "edit_history_tweet_ids": ["1600903255004831744"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600902726778589211"}], "id": "1600903255004831744", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"text": "It will be a decade or two to determine whether we are successful. The natural history of high risk SMM with observation or mild therapy is known. The goal with the Cure trials is to see if there is a plateau in disease free survival that\u2019s enduring &amp; far beyond what\u2019s expected.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 100, "end": 102, "probability": 0.7741, "type": "Other", "normalized_text": "SMM"}, {"start": 165, "end": 168, "probability": 0.696, "type": "Other", "normalized_text": "Cure"}]}, "created_at": "2022-12-08T17:18:48.000Z", "edit_history_tweet_ids": ["1600902726778589211"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600901502654361600"}], "id": "1600902726778589211", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"text": "These trials are part of a planned series of trials investigating whether the incurability of myeloma is related to the fact that we have traditionally started effective therapy only after the disease has spread and mutated to the point where it is no longer curable.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 94, "end": 100, "probability": 0.7607, "type": "Other", "normalized_text": "myeloma"}]}, "created_at": "2022-12-08T17:13:56.000Z", "edit_history_tweet_ids": ["1600901502654361600"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600901116744851458"}], "id": "1600901502654361600", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"entities": {"mentions": [{"start": 58, "end": 67, "username": "mvmateos", "id": "2239926566"}], "annotations": [{"start": 45, "end": 49, "probability": 0.3582, "type": "Organization", "normalized_text": "CESAR"}, {"start": 96, "end": 100, "probability": 0.4999, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 103, "end": 126, "url": "https://t.co/RAdqP5Dfl0", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Minimal Residual Disease Maria-Victoria Mateos, MD 1, Joaqu\u00edn Mart\u00ednez-L\u00f3pez, MD, PhD 2 *, Paula Rodr\u00edguez-Otero, MD, PhD 3 *, Jes\u00fas San-Miguel, MD, PhD 4, Veronica Gonzalez-Calle, MD, PhD 1 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html"}], "hashtags": [{"start": 95, "end": 101, "tag": "ASH22"}]}, "text": "Updated results from the 1st Cure trial, GEM-CESAR led by @mvmateos is also being presented at #ASH22\n\nhttps://t.co/RAdqP5Dfl0", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:12:24.000Z", "edit_history_tweet_ids": ["1600901116744851458"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600900413330374657"}], "id": "1600901116744851458", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"entities": {"mentions": [{"start": 23, "end": 33, "username": "myelomaMD", "id": "301568235"}], "annotations": [{"start": 74, "end": 79, "probability": 0.6945, "type": "Other", "normalized_text": "ASCENT"}, {"start": 142, "end": 148, "probability": 0.6294, "type": "Other", "normalized_text": "myeloma"}, {"start": 233, "end": 239, "probability": 0.5548, "type": "Other", "normalized_text": "myeloma"}], "urls": [{"start": 248, "end": 271, "url": "https://t.co/9fvVoPvwBM", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168930.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Risk-adapted Treatment Strategies in Myeloma and Related Conditions Hematology Disease Topics & Pathways: Research, clinical trials, Biological therapies, Antibody Therapy, Clinical Research, Plasma Cell Disorders, Combination therapy, Diseases, Therapies, Lymphoid Malignancies, Human, Minimal Residual Disease Shaji K Kumar, MD 1, Melissa Alsina, MD** 2, Betsy Laplant, MS 3 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168930.html"}, {"start": 272, "end": 295, "url": "https://t.co/GXdvY4J72z", "expanded_url": "https://twitter.com/VincentRK/status/1600900413330374657/photo/1", "display_url": "pic.twitter.com/GXdvY4J72z", "media_key": "3_1600900401452257285"}], "hashtags": [{"start": 3, "end": 9, "tag": "ASH22"}]}, "text": "At #ASH22 my colleague @myelomaMD will present the initial results of the ASCENT trial, aka the 2nd Cure trial to test the hypothesis whether myeloma can be cured if highly active combination therapy is given early at the smoldering myeloma stage. https://t.co/9fvVoPvwBM https://t.co/GXdvY4J72z", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:09:36.000Z", "edit_history_tweet_ids": ["1600900413330374657"], "author_id": "24261916", "lang": "en", "id": "1600900413330374657", "conversation_id": "1600900413330374657"}, {"text": "Why do you attend large medical meetings these days? #MedTwitter #ASH22\n\nIf other, add comment.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 54, "end": 63, "probability": 0.8911, "type": "Other", "normalized_text": "MedTwitter"}, {"start": 66, "end": 70, "probability": 0.5836, "type": "Other", "normalized_text": "ASH22"}], "hashtags": [{"start": 53, "end": 64, "tag": "MedTwitter"}, {"start": 65, "end": 71, "tag": "ASH22"}]}, "created_at": "2022-12-08T13:54:32.000Z", "edit_history_tweet_ids": ["1600851323590680577"], "author_id": "24261916", "lang": "en", "id": "1600851323590680577", "conversation_id": "1600851323590680577"}, {"entities": {"mentions": [{"start": 3, "end": 13, "username": "VincentRK", "id": "24261916"}, {"start": 40, "end": 55, "username": "ASH_hematology", "id": "84072624"}], "annotations": [{"start": 34, "end": 38, "probability": 0.5161, "type": "Other", "normalized_text": "ASH22"}, {"start": 56, "end": 62, "probability": 0.652, "type": "Other", "normalized_text": "myeloma"}, {"start": 76, "end": 82, "probability": 0.4934, "type": "Other", "normalized_text": "ASH22VR"}], "hashtags": [{"start": 33, "end": 39, "tag": "ASH22"}, {"start": 75, "end": 83, "tag": "ASH22VR"}]}, "text": "RT @VincentRK: Here are my Top 5 #ASH22 @ASH_hematology myeloma abstracts. #ASH22VR  \nLinks to the full abstract. As in the past, I left ou\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-08T13:49:29.000Z", "edit_history_tweet_ids": ["1600850052704047105"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1599075814553026562"}], "id": "1600850052704047105", "conversation_id": "1600850052704047105"}, {"entities": {"mentions": [{"start": 3, "end": 17, "username": "sehgalpathlab", "id": "912014667932979200"}], "annotations": [{"start": 66, "end": 69, "probability": 0.7411, "type": "Other", "normalized_text": "IMWG"}, {"start": 103, "end": 109, "probability": 0.4968, "type": "Other", "normalized_text": "myeloma"}]}, "text": "RT @sehgalpathlab: Great thread to revisit and understand the The IMWG updated diagnostic criteria for myeloma &amp; related disorders by @Vinc\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-08T13:41:33.000Z", "edit_history_tweet_ids": ["1600848054617133056"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600662755132207104"}], "id": "1600848054617133056", "conversation_id": "1600848054617133056"}, {"entities": {"mentions": [{"start": 236, "end": 247, "username": "LesokhinMD", "id": "1304124456"}], "annotations": [{"start": 13, "end": 17, "probability": 0.6762, "type": "Other", "normalized_text": "ASH22"}, {"start": 56, "end": 65, "probability": 0.634, "type": "Other", "normalized_text": "cevostamab"}, {"start": 79, "end": 85, "probability": 0.7488, "type": "Other", "normalized_text": "myeloma"}], "urls": [{"start": 255, "end": 278, "url": "https://t.co/R93xAhzkjo", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper157547.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study", "description": "Program: Oral and Poster Abstracts Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster I Hematology Disease Topics & Pathways: Research, clinical trials, Biological therapies, Bispecific Antibody Therapy, Clinical Research, Plasma Cell Disorders, drug development, Diseases, Therapies, Immunotherapy, Lymphoid Malignancies Alexander M Lesokhin, MD 1,2, Joshua Richter, MD 3, Suzanne Trudel 4, Adam D Cohen, MD 5, Andrew Spencer 6, Peter A Forsberg 7, Jacob P Laubach, MD 8", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper157547.html"}], "hashtags": [{"start": 12, "end": 18, "tag": "ASH22"}]}, "text": "I like this #ASH22 abstract examining fixed duration of cevostamab in relapsed myeloma. \n\nBispecifics will be extraordinarily expensive and carry significant infection risk with prolonged use. We need to study fixed duration treatment. @LesokhinMD et al. https://t.co/R93xAhzkjo", "source": "Twitter for iPhone", "created_at": "2022-12-08T13:40:17.000Z", "edit_history_tweet_ids": ["1600847739092602880"], "author_id": "24261916", "lang": "en", "id": "1600847739092602880", "conversation_id": "1600847739092602880"}, {"entities": {"mentions": [{"start": 0, "end": 13, "username": "PedalheadPHX", "id": "32760936"}, {"start": 14, "end": 29, "username": "ASH_hematology", "id": "84072624"}, {"start": 30, "end": 41, "username": "jmikhaelmd", "id": "2377190652"}]}, "text": "@PedalheadPHX @ASH_hematology @jmikhaelmd I have no idea whether I did or not. I\u2019ll just pick it up there. No stickers for me.", "source": "Twitter for iPhone", "created_at": "2022-12-08T13:30:03.000Z", "edit_history_tweet_ids": ["1600845162544254977"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600632832522702848"}], "id": "1600845162544254977", "in_reply_to_user_id": "32760936", "conversation_id": "1600632832522702848"}, {"text": "Once I make an assessment that someone is sealioning, I will permanently mute and not respond. \n\nI have not blocked anyone so far on Twitter. But I do mute rudeness and nonsense liberally.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 133, "end": 139, "probability": 0.9603, "type": "Other", "normalized_text": "Twitter"}]}, "created_at": "2022-12-08T13:27:26.000Z", "edit_history_tweet_ids": ["1600844501685137408"], "author_id": "24261916", "lang": "en", "id": "1600844501685137408", "conversation_id": "1600844501685137408"}, {"entities": {"mentions": [{"start": 0, "end": 8, "username": "wangyub", "id": "2170278304"}], "annotations": [{"start": 78, "end": 80, "probability": 0.6052, "type": "Other", "normalized_text": "MDE"}, {"start": 104, "end": 106, "probability": 0.6625, "type": "Other", "normalized_text": "MRI"}, {"start": 123, "end": 124, "probability": 0.6856, "type": "Other", "normalized_text": "MM"}, {"start": 263, "end": 265, "probability": 0.6372, "type": "Other", "normalized_text": "FLC"}]}, "text": "@wangyub As always use judgment. If you have 40% bone marrow PCs and the only MDE is 2 focal lesions on MRI, that\u2019s likely MM and you wouldn\u2019t need to biopsy or wait. If you have only 12% PCs the you may want to biopsy or wait and repeat imaging. Also depends on FLC level and ratio.", "source": "Twitter for iPhone", "created_at": "2022-12-08T06:30:23.000Z", "edit_history_tweet_ids": ["1600739549784965120"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600738885784330242"}], "id": "1600739549784965120", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"entities": {"mentions": [{"start": 0, "end": 8, "username": "wangyub", "id": "2170278304"}], "annotations": [{"start": 58, "end": 60, "probability": 0.5254, "type": "Other", "normalized_text": "MRI"}, {"start": 82, "end": 84, "probability": 0.415, "type": "Other", "normalized_text": "MDE"}, {"start": 181, "end": 183, "probability": 0.6077, "type": "Other", "normalized_text": "MRI"}]}, "text": "@wangyub The criteria are very specific on how to use the MRI. If that\u2019s the only MDE you need bone marrow with &gt;=10% clonal plasma cells and 2 or more definite focal lesions on MRI at least 5mm in size. If in doubt wait 3-6 months and repeat. Diffuse abnormalities or signal is not MDE.", "source": "Twitter for iPhone", "created_at": "2022-12-08T06:27:45.000Z", "edit_history_tweet_ids": ["1600738885784330242"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600720749224136704"}], "id": "1600738885784330242", "in_reply_to_user_id": "2170278304", "conversation_id": "1600533243392057344"}, {"entities": {"mentions": [{"start": 3, "end": 16, "username": "AkivaDiamond", "id": "4051359136"}], "annotations": [{"start": 43, "end": 46, "probability": 0.7376, "type": "Other", "normalized_text": "IMWG"}]}, "text": "RT @AkivaDiamond: Great thread on the 2014 IMWG criteria. Several points in this brief thread are often misunderstood. I want to highlight\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-08T02:44:37.000Z", "edit_history_tweet_ids": ["1600682734115921920"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600568812025298961"}], "id": "1600682734115921920", "conversation_id": "1600682734115921920"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 15, "end": 29, "username": "CyclingDoctor", "id": "23036480"}, {"start": 30, "end": 42, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 43, "end": 55, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 56, "end": 71, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 72, "end": 81, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 82, "end": 96, "username": "DavidSteensma", "id": "2739065578"}, {"start": 97, "end": 107, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 108, "end": 121, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 122, "end": 132, "username": "myelomaMD", "id": "301568235"}, {"start": 133, "end": 142, "username": "Geoff_Uy", "id": "985139345928736768"}]}, "text": "@MichaelJSlade @CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @ManniMD1 @DavidSteensma @bdermanmd @VPrasadMDMPH @myelomaMD @Geoff_Uy If you are not focused on a disease it\u2019s still good to decide whether your focus is on clinical abstracts or lab and then do the same exercise of picking about 25 ones you really are interested in. \n\nAttend a couple oral sessions a day and walk by the posters and meet colleagues.", "source": "Twitter for iPhone", "created_at": "2022-12-08T02:40:50.000Z", "edit_history_tweet_ids": ["1600681782286102528"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600673744728489984"}], "id": "1600681782286102528", "in_reply_to_user_id": "24261916", "conversation_id": "1600642889280798721"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 15, "end": 29, "username": "CyclingDoctor", "id": "23036480"}, {"start": 30, "end": 42, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 43, "end": 55, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 56, "end": 71, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 72, "end": 81, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 82, "end": 96, "username": "DavidSteensma", "id": "2739065578"}, {"start": 97, "end": 107, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 108, "end": 121, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 122, "end": 132, "username": "myelomaMD", "id": "301568235"}, {"start": 133, "end": 142, "username": "Geoff_Uy", "id": "985139345928736768"}], "annotations": [{"start": 216, "end": 222, "probability": 0.6069, "type": "Other", "normalized_text": "myeloma"}]}, "text": "@MichaelJSlade @CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @ManniMD1 @DavidSteensma @bdermanmd @VPrasadMDMPH @myelomaMD @Geoff_Uy I usually apply the oral session filter and the field I\u2019m interested in (myeloma) and quickly scan through the abstracts, printing ones I feel are important for me. The exercise then of picking my top 5 each year ensures I read the ones I print (about ~25) closely.", "source": "Twitter for iPhone", "created_at": "2022-12-08T02:08:54.000Z", "edit_history_tweet_ids": ["1600673744728489984"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600642889280798721"}], "id": "1600673744728489984", "in_reply_to_user_id": "626650397", "conversation_id": "1600642889280798721"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "szusmani", "id": "83911786"}], "annotations": [{"start": 29, "end": 32, "probability": 0.5858, "type": "Other", "normalized_text": "Saad"}]}, "text": "@szusmani Absolutely. Thanks Saad.", "source": "Twitter for iPhone", "created_at": "2022-12-07T19:06:36.000Z", "edit_history_tweet_ids": ["1600567467725701125"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600554971971436574"}], "id": "1600567467725701125", "in_reply_to_user_id": "83911786", "conversation_id": "1600554971971436574"}, {"entities": {"mentions": [{"start": 3, "end": 12, "username": "szusmani", "id": "83911786"}], "annotations": [{"start": 30, "end": 34, "probability": 0.6647, "type": "Other", "normalized_text": "ASH22"}, {"start": 85, "end": 88, "probability": 0.5754, "type": "Other", "normalized_text": "mmsm"}], "hashtags": [{"start": 29, "end": 35, "tag": "ASH22"}, {"start": 84, "end": 89, "tag": "mmsm"}]}, "text": "RT @szusmani: This thread \ud83d\udc47\ud83c\udffd #ASH22, a testament to the collaborative nature of the #mmsm community.", "source": "Twitter for iPhone", "created_at": "2022-12-07T19:06:26.000Z", "edit_history_tweet_ids": ["1600567426382446615"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600554971971436574"}], "id": "1600567426382446615", "conversation_id": "1600567426382446615"}, {"entities": {"mentions": [{"start": 136, "end": 146, "username": "DavidP4AD", "id": "20688251"}, {"start": 156, "end": 170, "username": "costplusdrugs", "id": "1284331089977151488"}], "annotations": [{"start": 112, "end": 121, "probability": 0.8013, "type": "Other", "normalized_text": "MedTwitter"}], "urls": [{"start": 171, "end": 194, "url": "https://t.co/GzfDFiSrZR", "expanded_url": "https://twitter.com/costplusdrugs/status/1600518796665569282", "display_url": "twitter.com/costplusdrugs/\u2026"}], "hashtags": [{"start": 111, "end": 122, "tag": "MedTwitter"}, {"start": 123, "end": 135, "tag": "Insulin4all"}]}, "text": "Im not an insulin user. But as physician advocate for lower insulin prices, I think this will be a life saver. #MedTwitter #Insulin4all @DavidP4AD \n\nThanks @costplusdrugs https://t.co/GzfDFiSrZR", "source": "Twitter for iPhone", "created_at": "2022-12-07T17:34:54.000Z", "edit_history_tweet_ids": ["1600544391491469316"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600518796665569282"}], "id": "1600544391491469316", "conversation_id": "1600544391491469316"}, {"text": "For those interested the paper which was previously the most cited paper ever in myeloma was the 1975 Durie Salmon staging system with 3940 citations.  \n\n(Citations as captured in Google Scholar)", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 81, "end": 87, "probability": 0.5643, "type": "Other", "normalized_text": "myeloma"}, {"start": 102, "end": 113, "probability": 0.6477, "type": "Person", "normalized_text": "Durie Salmon"}, {"start": 180, "end": 193, "probability": 0.8889, "type": "Other", "normalized_text": "Google Scholar"}]}, "created_at": "2022-12-07T16:52:52.000Z", "edit_history_tweet_ids": ["1600533815000186880"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533278792073219"}], "id": "1600533815000186880", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"entities": {"mentions": [{"start": 143, "end": 155, "username": "thanosdimop", "id": "3419708038"}, {"start": 156, "end": 165, "username": "mvmateos", "id": "2239926566"}, {"start": 166, "end": 176, "username": "myelomaMD", "id": "301568235"}, {"start": 177, "end": 190, "username": "BrianDurieMD", "id": "339306345"}, {"start": 191, "end": 205, "username": "SagarLonialMD", "id": "2289851689"}, {"start": 206, "end": 215, "username": "szusmani", "id": "83911786"}, {"start": 216, "end": 229, "username": "ADispenzieri", "id": "2172483547"}, {"start": 230, "end": 244, "username": "sykristinsson", "id": "3078258341"}, {"start": 245, "end": 259, "username": "DrOlaLandgren", "id": "2257190339"}, {"start": 260, "end": 270, "username": "mbeksac56", "id": "2171123355"}, {"start": 271, "end": 287, "username": "BrunoPaiva_UNAV", "id": "1335161063382376448"}], "annotations": [{"start": 39, "end": 42, "probability": 0.3832, "type": "Other", "normalized_text": "IMWG"}, {"start": 61, "end": 76, "probability": 0.541, "type": "Person", "normalized_text": "Jesus San Miguel"}, {"start": 79, "end": 95, "probability": 0.5077, "type": "Other", "normalized_text": "Giampaolo Merlini"}, {"start": 98, "end": 109, "probability": 0.9166, "type": "Person", "normalized_text": "Ken Anderson"}, {"start": 112, "end": 119, "probability": 0.8737, "type": "Person", "normalized_text": "Bob Kyle"}, {"start": 134, "end": 140, "probability": 0.8614, "type": "Other", "normalized_text": "Twitter"}], "urls": [{"start": 288, "end": 311, "url": "https://t.co/dmqkEouveg", "expanded_url": "https://twitter.com/VincentRK/status/1600533278792073219/photo/1", "display_url": "pic.twitter.com/dmqkEouveg", "media_key": "3_1600533275109376000"}]}, "text": "12/ This is all thanks &amp; credit to IMWG &amp; coauthors. Jesus San Miguel, Giampaolo Merlini, Ken Anderson, Bob Kyle. Many are on Twitter: @thanosdimop @mvmateos @myelomaMD @BrianDurieMD @SagarLonialMD @szusmani @ADispenzieri @sykristinsson @DrOlaLandgren @mbeksac56 @BrunoPaiva_UNAV https://t.co/dmqkEouveg", "source": "Twitter for iPhone", "created_at": "2022-12-07T16:50:44.000Z", "edit_history_tweet_ids": ["1600533278792073219"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533273658068993"}], "id": "1600533278792073219", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "11/ There\u2019s a lot more in this paper. The authors worked on many drafts to ensure we got it right and had consensus. \n\nI have never worked on a paper where every single sentence has so much importance and meaning as in this paper.", "source": "Twitter for iPhone", "created_at": "2022-12-07T16:50:43.000Z", "edit_history_tweet_ids": ["1600533273658068993"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533271296753665"}], "id": "1600533273658068993", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "10/ CRAB features do not need to be symptomatic.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 4, "end": 7, "probability": 0.686, "type": "Other", "normalized_text": "CRAB"}]}, "created_at": "2022-12-07T16:50:43.000Z", "edit_history_tweet_ids": ["1600533271296753665"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533269208043524"}], "id": "1600533271296753665", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "9/ Infections, suppression of uninvolved immunoglobulins are not considered myeloma defining events. Too non specific. Patients must meet one of the 7 myeloma defining events defined in the criteria to be considered as having myeloma.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 151, "end": 157, "probability": 0.5329, "type": "Other", "normalized_text": "myeloma"}]}, "created_at": "2022-12-07T16:50:42.000Z", "edit_history_tweet_ids": ["1600533269208043524"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533267152789504"}], "id": "1600533269208043524", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "8/ Presence of clonal plasma cells in the bone marrow biopsy is not needed for diagnosis of myeloma. Presence of a biopsy proven plasmacytoma with another myeloma defining event is sufficient.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 15, "end": 27, "probability": 0.5625, "type": "Other", "normalized_text": "clonal plasma"}, {"start": 54, "end": 59, "probability": 0.6269, "type": "Other", "normalized_text": "biopsy"}, {"start": 92, "end": 98, "probability": 0.7516, "type": "Other", "normalized_text": "myeloma"}, {"start": 129, "end": 140, "probability": 0.7141, "type": "Other", "normalized_text": "plasmacytoma"}, {"start": 155, "end": 161, "probability": 0.6979, "type": "Other", "normalized_text": "myeloma"}]}, "created_at": "2022-12-07T16:50:42.000Z", "edit_history_tweet_ids": ["1600533267152789504"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533265529438209"}], "id": "1600533267152789504", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "7/ Presence of serum or urine M protein is not necessary for myeloma diagnosis. Non secretory myeloma is myeloma and treated as such. It\u2019s not a separate disease. It\u2019s more of a description, and it\u2019s understood that monitoring will be different in such patients.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 32, "end": 38, "probability": 0.4887, "type": "Other", "normalized_text": "protein"}, {"start": 61, "end": 67, "probability": 0.7069, "type": "Other", "normalized_text": "myeloma"}, {"start": 105, "end": 111, "probability": 0.5199, "type": "Other", "normalized_text": "myeloma"}]}, "created_at": "2022-12-07T16:50:41.000Z", "edit_history_tweet_ids": ["1600533265529438209"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533263629557763"}], "id": "1600533265529438209", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "6/ Only light chain cast nephropathy qualifies as a myeloma defining renal event. All other renal lesions attributable to monoclonal protein are considered unique disorders and do not automatically mean malignancy or meet the criteria for myeloma diagnosis.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 25, "end": 35, "probability": 0.8197, "type": "Other", "normalized_text": "nephropathy"}, {"start": 52, "end": 58, "probability": 0.6255, "type": "Other", "normalized_text": "myeloma"}, {"start": 122, "end": 131, "probability": 0.5397, "type": "Other", "normalized_text": "monoclonal"}, {"start": 239, "end": 245, "probability": 0.7854, "type": "Other", "normalized_text": "myeloma"}]}, "created_at": "2022-12-07T16:50:41.000Z", "edit_history_tweet_ids": ["1600533263629557763"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533262098927617"}], "id": "1600533263629557763", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "5/ Clarification and recommendations for   advanced imaging (CT, PET-CT ) to detect lytic bone lesions. \n\nTo distinguish MM from SMM, MRI imaging may be needed.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 65, "end": 68, "probability": 0.492, "type": "Other", "normalized_text": "PET-"}, {"start": 121, "end": 122, "probability": 0.5566, "type": "Other", "normalized_text": "MM"}, {"start": 129, "end": 131, "probability": 0.7194, "type": "Other", "normalized_text": "SMM"}, {"start": 134, "end": 136, "probability": 0.6508, "type": "Other", "normalized_text": "MRI"}]}, "created_at": "2022-12-07T16:50:40.000Z", "edit_history_tweet_ids": ["1600533262098927617"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533259494227968"}], "id": "1600533262098927617", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "4/ MGUS was formally classified into 3 types with specific diagnostic criteria outlined for each. #ASH22 #MedTwitter https://t.co/f7Cjf06vM3", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 3, "end": 6, "probability": 0.6235, "type": "Organization", "normalized_text": "MGUS"}, {"start": 99, "end": 103, "probability": 0.6199, "type": "Other", "normalized_text": "ASH22"}, {"start": 106, "end": 115, "probability": 0.8218, "type": "Other", "normalized_text": "MedTwitter"}], "urls": [{"start": 117, "end": 140, "url": "https://t.co/f7Cjf06vM3", "expanded_url": "https://twitter.com/VincentRK/status/1600533259494227968/photo/1", "display_url": "pic.twitter.com/f7Cjf06vM3", "media_key": "3_1600533256176373761"}], "hashtags": [{"start": 98, "end": 104, "tag": "ASH22"}, {"start": 105, "end": 116, "tag": "MedTwitter"}]}, "created_at": "2022-12-07T16:50:40.000Z", "edit_history_tweet_ids": ["1600533259494227968"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533254372745220"}], "id": "1600533259494227968", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "3/ We simultaneously updated the diagnostic criteria for related plasma cell disorders including MGUS, SMM, and solitary plasmacytoma. https://t.co/D9l07jzAP6", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 97, "end": 100, "probability": 0.6413, "type": "Other", "normalized_text": "MGUS"}, {"start": 103, "end": 105, "probability": 0.8006, "type": "Other", "normalized_text": "SMM"}, {"start": 121, "end": 132, "probability": 0.6278, "type": "Other", "normalized_text": "plasmacytoma"}], "urls": [{"start": 135, "end": 158, "url": "https://t.co/D9l07jzAP6", "expanded_url": "https://twitter.com/VincentRK/status/1600533254372745220/photo/1", "display_url": "pic.twitter.com/D9l07jzAP6", "media_key": "3_1600533251898097666"}]}, "created_at": "2022-12-07T16:50:38.000Z", "edit_history_tweet_ids": ["1600533254372745220"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533249339572227"}], "id": "1600533254372745220", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "2/ The paradigm shifting  change was including 3 biomarkers that were associated with 80% or greater probability of progression within 2 years as myeloma defining events on top of CRAB. \n\n&gt;100 myeloma experts gave input for the paper. #ASH22 #MedTwitter https://t.co/ZoIwF4QgOZ", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 146, "end": 152, "probability": 0.6029, "type": "Other", "normalized_text": "myeloma"}, {"start": 180, "end": 183, "probability": 0.6512, "type": "Other", "normalized_text": "CRAB"}, {"start": 196, "end": 202, "probability": 0.4858, "type": "Other", "normalized_text": "myeloma"}, {"start": 239, "end": 243, "probability": 0.5844, "type": "Other", "normalized_text": "ASH22"}, {"start": 246, "end": 255, "probability": 0.8445, "type": "Other", "normalized_text": "MedTwitter"}], "urls": [{"start": 257, "end": 280, "url": "https://t.co/ZoIwF4QgOZ", "expanded_url": "https://twitter.com/VincentRK/status/1600533249339572227/photo/1", "display_url": "pic.twitter.com/ZoIwF4QgOZ", "media_key": "3_1600533245560487936"}], "hashtags": [{"start": 238, "end": 244, "tag": "ASH22"}, {"start": 245, "end": 256, "tag": "MedTwitter"}]}, "created_at": "2022-12-07T16:50:37.000Z", "edit_history_tweet_ids": ["1600533249339572227"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533243392057344"}], "id": "1600533249339572227", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"entities": {"mentions": [{"start": 149, "end": 164, "username": "TheLancetOncol", "id": "50265238"}], "annotations": [{"start": 18, "end": 22, "probability": 0.6619, "type": "Other", "normalized_text": "ASH22"}, {"start": 29, "end": 32, "probability": 0.6619, "type": "Other", "normalized_text": "IMWG"}, {"start": 166, "end": 175, "probability": 0.8809, "type": "Other", "normalized_text": "MedTwitter"}, {"start": 244, "end": 247, "probability": 0.6294, "type": "Other", "normalized_text": "IMWG"}], "urls": [{"start": 177, "end": 200, "url": "https://t.co/61ohPFLtGi", "expanded_url": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70442-5/fulltext", "display_url": "thelancet.com/journals/lanon\u2026", "status": 200, "title": "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma", "description": "This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identification of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients.", "unwound_url": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70442-5/fulltext"}], "hashtags": [{"start": 17, "end": 23, "tag": "ASH22"}, {"start": 165, "end": 176, "tag": "MedTwitter"}]}, "text": "Just in time for #ASH22\n\nThe IMWG updated diagnostic criteria for myeloma &amp; related disorders has just become the most cited myeloma paper ever. @TheLancetOncol #MedTwitter https://t.co/61ohPFLtGi\n\nI was honored to lead this effort for the IMWG. A thread on the main changes. \n1/", "source": "Twitter for iPhone", "created_at": "2022-12-07T16:50:36.000Z", "edit_history_tweet_ids": ["1600533243392057344"], "author_id": "24261916", "lang": "en", "id": "1600533243392057344", "conversation_id": "1600533243392057344"}, {"text": "Summary of the active drugs in myeloma and their mechanism of action. https://t.co/GUVWkcrL2z", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 31, "end": 37, "probability": 0.7925, "type": "Other", "normalized_text": "myeloma"}], "urls": [{"start": 70, "end": 93, "url": "https://t.co/GUVWkcrL2z", "expanded_url": "https://twitter.com/vincentrk/status/1599840937622265856", "display_url": "twitter.com/vincentrk/stat\u2026"}]}, "created_at": "2022-12-07T03:07:05.000Z", "edit_history_tweet_ids": ["1600325998607745024"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1599840937622265856"}], "id": "1600325998607745024", "conversation_id": "1600325998607745024"}, {"text": "https://t.co/R8CHM8qqPf", "source": "Twitter for iPhone", "entities": {"urls": [{"start": 0, "end": 23, "url": "https://t.co/R8CHM8qqPf", "expanded_url": "https://twitter.com/i/spaces/1vAGRAmWdpgKl", "display_url": "twitter.com/i/spaces/1vAGR\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600250316762468352/9Ma_6JVi?format=jpg&name=orig", "width": 1200, "height": 630}, {"url": "https://pbs.twimg.com/news_img/1600250316762468352/9Ma_6JVi?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Happening now: ASH22 Myeloma updates", "description": "Vincent Rajkumar\u2019s Space \u00b7 0 listening \u00b7 Where live audio conversations happen", "unwound_url": "https://twitter.com/i/spaces/1vAGRAmWdpgKl"}]}, "created_at": "2022-12-06T22:06:21.000Z", "edit_history_tweet_ids": ["1600250315189547008"], "author_id": "24261916", "lang": "zxx", "id": "1600250315189547008", "conversation_id": "1600250315189547008"}, {"entities": {"mentions": [{"start": 3, "end": 19, "username": "BenjaminJStults", "id": "2297835854"}]}, "text": "RT @BenjaminJStults: Very grateful to have received my flu shot in mid-October.\n\nMake sure to get yours!", "source": "Twitter for iPhone", "created_at": "2022-12-06T21:21:12.000Z", "edit_history_tweet_ids": ["1600238953042309120"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600237966147825664"}], "id": "1600238953042309120", "conversation_id": "1600238953042309120"}, {"entities": {"mentions": [{"start": 69, "end": 85, "username": "landmanspeaking", "id": "2654964164"}, {"start": 86, "end": 96, "username": "voxdotcom", "id": "2347049341"}], "annotations": [{"start": 5, "end": 6, "probability": 0.9632, "type": "Place", "normalized_text": "US"}, {"start": 99, "end": 103, "probability": 0.9559, "type": "Other", "normalized_text": "Covid"}, {"start": 132, "end": 140, "probability": 0.6181, "type": "Other", "normalized_text": "influenza"}], "urls": [{"start": 197, "end": 220, "url": "https://t.co/GQ2RjHFi00", "expanded_url": "https://www.vox.com/platform/amp/2022/12/6/23494948/flu-influenza-rsv-covid-vaccine-chart-tripledemic-tridemic", "display_url": "vox.com/platform/amp/2\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600237133351903232/Hwbkdjr9?format=jpg&name=orig", "width": 1400, "height": 1050}, {"url": "https://pbs.twimg.com/news_img/1600237133351903232/Hwbkdjr9?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "The US has never recorded this many positive flu tests in one week", "description": "We use cookies and other tracking technologies to improve your browsing experience on our site, show personalized content and targeted ads, analyze site traffic, and understand where our audiences come from. To learn more or opt-out, read our Cookie Policy. Please also read our Privacy Notice and Terms of Use, which became effective December 20, 2019. By choosing I Accept, you consent to our use of cookies and other tracking technologies. And health care systems are getting absolutely crushed ... again.", "unwound_url": "https://www.vox.com/platform/amp/2022/12/6/23494948/flu-influenza-rsv-covid-vaccine-chart-tripledemic-tridemic"}]}, "text": "\u201cThe US has never recorded this many positive flu tests in one week\u201d @landmanspeaking @voxdotcom \n\nCovid precautions helped contain influenza the last two years. Now hospitals face a tough winter. https://t.co/GQ2RjHFi00", "source": "Twitter for iPhone", "created_at": "2022-12-06T21:13:57.000Z", "edit_history_tweet_ids": ["1600237131183448064"], "author_id": "24261916", "lang": "en", "id": "1600237131183448064", "conversation_id": "1600237131183448064"}, {"entities": {"mentions": [{"start": 75, "end": 90, "username": "BloodCancerJnl", "id": "1417061180997345288"}], "annotations": [{"start": 26, "end": 30, "probability": 0.6994, "type": "Other", "normalized_text": "ASH22"}, {"start": 149, "end": 151, "probability": 0.4633, "type": "Organization", "normalized_text": "BCJ"}, {"start": 168, "end": 171, "probability": 0.5419, "type": "Other", "normalized_text": "Heme"}], "hashtags": [{"start": 25, "end": 31, "tag": "ASH22"}]}, "text": "If you are presenting at #ASH22 and have an important finding suitable for @BloodCancerJnl contact me. DM the abstract link. I\u2019ll get back to you. \n\nBCJ is in Top 5 of Heme journals publishing original research.", "source": "Twitter for iPhone", "created_at": "2022-12-06T21:06:07.000Z", "edit_history_tweet_ids": ["1600235160967925763"], "author_id": "24261916", "lang": "en", "id": "1600235160967925763", "conversation_id": "1600235160967925763"}, {"text": "Patients have already paid their premiums. They have deductibles and copays. They need assurance that when they need healthcare they will get the best care they need and what the physician they trust recommends.", "source": "Twitter for iPhone", "created_at": "2022-12-06T20:43:20.000Z", "edit_history_tweet_ids": ["1600229425387171840"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600226720157605888"}], "id": "1600229425387171840", "in_reply_to_user_id": "24261916", "conversation_id": "1600226720157605888"}, {"entities": {"mentions": [{"start": 0, "end": 16, "username": "SpaceFo25925369", "id": "1011728551647817729"}]}, "text": "@SpaceFo25925369 Yes. It\u2019s a big hassle. I Mm thinking of this in terms of how to move forward with advocacy.", "source": "Twitter for iPhone", "created_at": "2022-12-06T20:41:06.000Z", "edit_history_tweet_ids": ["1600228862218027008"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600228397799510016"}], "id": "1600228862218027008", "in_reply_to_user_id": "1011728551647817729", "conversation_id": "1600226720157605888"}, {"text": "Vulnerable patients who are already suffering from their illness should not have the added problem of fighting with insurance companies for coverage. Reform is needed.", "source": "Twitter for iPhone", "created_at": "2022-12-06T20:32:35.000Z", "edit_history_tweet_ids": ["1600226720157605888"], "author_id": "24261916", "lang": "en", "id": "1600226720157605888", "conversation_id": "1600226720157605888"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "DrTJM_MD", "id": "1365049914674266116"}], "annotations": [{"start": 55, "end": 56, "probability": 0.5357, "type": "Other", "normalized_text": "Rd"}, {"start": 61, "end": 63, "probability": 0.6602, "type": "Other", "normalized_text": "DRd"}, {"start": 149, "end": 151, "probability": 0.6072, "type": "Other", "normalized_text": "SMM"}, {"start": 210, "end": 212, "probability": 0.7648, "type": "Other", "normalized_text": "Len"}, {"start": 217, "end": 219, "probability": 0.7415, "type": "Other", "normalized_text": "Len"}], "urls": [{"start": 264, "end": 287, "url": "https://t.co/iJ4X6XOI2g", "expanded_url": "https://www.nature.com/articles/s41408-022-00719-0", "display_url": "nature.com/articles/s4140\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600224808364519424/kgsTzsAX?format=png&name=orig", "width": 1350, "height": 779}, {"url": "https://pbs.twimg.com/news_img/1600224808364519424/kgsTzsAX?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Smoldering multiple myeloma current treatment algorithms", "description": "Blood Cancer Journal - Smoldering multiple myeloma current treatment algorithms", "unwound_url": "https://www.nature.com/articles/s41408-022-00719-0?error=cookies_not_supported&code=6caa6366-06b2-4e22-9207-8f88e957c651"}]}, "text": "@DrTJM_MD We enroll patients on trials as the default. Rd vs DRd is the current phase III. \n\nOff study, practice varies. Most of us who have studied SMM in detail recommend treating newly diagnosed HR SMM with Len or Len/dex for 2 years as outlined in this paper. https://t.co/iJ4X6XOI2g", "source": "Twitter for iPhone", "created_at": "2022-12-06T20:24:58.000Z", "edit_history_tweet_ids": ["1600224804895760384"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600223465935867904"}], "id": "1600224804895760384", "in_reply_to_user_id": "1365049914674266116", "conversation_id": "1599838360419213312"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "DrTJM_MD", "id": "1365049914674266116"}], "annotations": [{"start": 44, "end": 46, "probability": 0.3801, "type": "Other", "normalized_text": "SMM"}, {"start": 68, "end": 70, "probability": 0.4796, "type": "Other", "normalized_text": "RCT"}, {"start": 99, "end": 101, "probability": 0.524, "type": "Other", "normalized_text": "Len"}, {"start": 106, "end": 107, "probability": 0.5239, "type": "Other", "normalized_text": "Rd"}, {"start": 160, "end": 162, "probability": 0.4555, "type": "Other", "normalized_text": "VRd"}, {"start": 187, "end": 188, "probability": 0.6204, "type": "Place", "normalized_text": "US"}]}, "text": "@DrTJM_MD We could recommend triplet for HR SMM now. But we lack of RCT data that it\u2019s better than Len or Rd. Why we do the RCTs \n\nSecondly, you and I can give VRd or DRd to well insured US patients now. Most others in the world we won\u2019t be able to help absent RCTs and regulatory approval.", "source": "Twitter for iPhone", "created_at": "2022-12-06T20:12:13.000Z", "edit_history_tweet_ids": ["1600221593694654466"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600220835490320384"}], "id": "1600221593694654466", "in_reply_to_user_id": "24261916", "conversation_id": "1599838360419213312"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "DrTJM_MD", "id": "1365049914674266116"}], "annotations": [{"start": 23, "end": 26, "probability": 0.4687, "type": "Other", "normalized_text": "RCTs"}, {"start": 31, "end": 33, "probability": 0.6297, "type": "Other", "normalized_text": "Obs"}, {"start": 38, "end": 40, "probability": 0.4998, "type": "Other", "normalized_text": "Len"}, {"start": 46, "end": 48, "probability": 0.5277, "type": "Other", "normalized_text": "Len"}, {"start": 50, "end": 52, "probability": 0.5288, "type": "Other", "normalized_text": "Dex"}, {"start": 59, "end": 61, "probability": 0.4254, "type": "Other", "normalized_text": "obs"}, {"start": 66, "end": 69, "probability": 0.4447, "type": "Person", "normalized_text": "Dara"}, {"start": 153, "end": 156, "probability": 0.447, "type": "Other", "normalized_text": "RCTs"}, {"start": 172, "end": 173, "probability": 0.5777, "type": "Other", "normalized_text": "Rd"}, {"start": 178, "end": 180, "probability": 0.5686, "type": "Other", "normalized_text": "DRd"}, {"start": 187, "end": 188, "probability": 0.5613, "type": "Other", "normalized_text": "Rd"}, {"start": 193, "end": 197, "probability": 0.5679, "type": "Other", "normalized_text": "IsaRd"}, {"start": 233, "end": 235, "probability": 0.4506, "type": "Other", "normalized_text": "SMM"}]}, "text": "@DrTJM_MD We have done RCTs of Obs vs Len and Len/Dex. And obs vs Dara (results not available). \n\nThe hypothesis is triplet will be superior. That\u2019s why RCTs are going on. Rd vs DRd; and Rd vs IsaRd. \n\nWe don\u2019t recommend treating HR SMM indefinitely. It\u2019s 2 years and stop.", "source": "Twitter for iPhone", "created_at": "2022-12-06T20:09:12.000Z", "edit_history_tweet_ids": ["1600220835490320384"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600194954738905088"}], "id": "1600220835490320384", "in_reply_to_user_id": "1365049914674266116", "conversation_id": "1599838360419213312"}, {"entities": {"mentions": [{"start": 3, "end": 14, "username": "doctorpemm", "id": "2429552622"}, {"start": 90, "end": 105, "username": "MDAndersonNews", "id": "14062554"}], "annotations": [{"start": 70, "end": 77, "probability": 0.4746, "type": "Other", "normalized_text": "Educator"}]}, "text": "RT @doctorpemm: \ud83d\udc49\ud83d\udc49\ud83d\udc49Deeply honored to be recognized today as a Faculty Educator Awardee by @MDAndersonNews !!!! Special\ud83d\ude4f\ud83c\udffe to Dr @DianeBodurk\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-06T19:59:23.000Z", "edit_history_tweet_ids": ["1600218365846384641"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600183100629131264"}], "id": "1600218365846384641", "conversation_id": "1600218365846384641"}, {"entities": {"mentions": [{"start": 0, "end": 11, "username": "doctorpemm", "id": "2429552622"}, {"start": 12, "end": 27, "username": "MDAndersonNews", "id": "14062554"}, {"start": 28, "end": 41, "username": "DianeBodurka", "id": "938869906531110915"}, {"start": 42, "end": 57, "username": "Transplant_Doc", "id": "162587280"}, {"start": 58, "end": 72, "username": "DrHKantarjian", "id": "897448268740923392"}, {"start": 73, "end": 82, "username": "mkonople", "id": "1597228226"}, {"start": 83, "end": 96, "username": "BldCancerDoc", "id": "2809497047"}, {"start": 97, "end": 105, "username": "mtmdphd", "id": "190337035"}, {"start": 106, "end": 116, "username": "jaltmanmd", "id": "2228604786"}, {"start": 117, "end": 130, "username": "sanamloghavi", "id": "3076847052"}, {"start": 131, "end": 138, "username": "KMirza", "id": "28108352"}, {"start": 139, "end": 152, "username": "sanjayvdesai", "id": "2152550867"}, {"start": 153, "end": 165, "username": "NitinJainMD", "id": "2756778469"}], "annotations": [{"start": 175, "end": 180, "probability": 0.6091, "type": "Other", "normalized_text": "Naveen"}]}, "text": "@doctorpemm @MDAndersonNews @DianeBodurka @Transplant_Doc @DrHKantarjian @mkonople @BldCancerDoc @mtmdphd @jaltmanmd @sanamloghavi @KMirza @sanjayvdesai @NitinJainMD Congrats Naveen! Awesome", "source": "Twitter for iPhone", "created_at": "2022-12-06T19:59:21.000Z", "edit_history_tweet_ids": ["1600218357327798272"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600183100629131264"}], "id": "1600218357327798272", "in_reply_to_user_id": "2429552622", "conversation_id": "1600183100629131264"}, {"entities": {"mentions": [{"start": 3, "end": 13, "username": "imedverse", "id": "1886086740"}, {"start": 60, "end": 70, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 51, "end": 57, "probability": 0.6817, "type": "Other", "normalized_text": "myeloma"}, {"start": 72, "end": 78, "probability": 0.6497, "type": "Other", "normalized_text": "myeloma"}, {"start": 104, "end": 113, "probability": 0.5259, "type": "Other", "normalized_text": "MedTwitter"}], "hashtags": [{"start": 71, "end": 79, "tag": "myeloma"}, {"start": 80, "end": 95, "tag": "TipsForNewDocs"}, {"start": 96, "end": 102, "tag": "MedEd"}, {"start": 103, "end": 114, "tag": "MedTwitter"}, {"start": 115, "end": 124, "tag": "medicine"}, {"start": 125, "end": 133, "tag": "medical"}]}, "text": "RT @imedverse: algorithms for current treatment of myeloma\n\n@VincentRK #myeloma #TipsForNewDocs #MedEd #MedTwitter #medicine #medical #medi\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-06T18:35:02.000Z", "edit_history_tweet_ids": ["1600197138129903616"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600086917919698944"}], "id": "1600197138129903616", "conversation_id": "1600197138129903616"}, {"entities": {"mentions": [{"start": 74, "end": 83, "username": "szusmani", "id": "83911786"}, {"start": 84, "end": 98, "username": "SagarLonialMD", "id": "2289851689"}, {"start": 99, "end": 107, "username": "Rfonsi1", "id": "146995555"}, {"start": 108, "end": 121, "username": "NoopurRajeMD", "id": "980935198870261760"}, {"start": 122, "end": 136, "username": "sykristinsson", "id": "3078258341"}, {"start": 137, "end": 147, "username": "myelomaMD", "id": "301568235"}], "annotations": [{"start": 0, "end": 13, "probability": 0.7664, "type": "Other", "normalized_text": "Twitter Spaces"}, {"start": 40, "end": 44, "probability": 0.5891, "type": "Other", "normalized_text": "ASH22"}], "hashtags": [{"start": 39, "end": 45, "tag": "ASH22"}]}, "text": "Twitter Spaces today at 5pm eastern on #ASH22 \n\nAbstracts and highlights. @szusmani @SagarLonialMD @Rfonsi1 @NoopurRajeMD @sykristinsson @myelomaMD", "source": "Twitter for iPhone", "created_at": "2022-12-06T17:56:39.000Z", "edit_history_tweet_ids": ["1600187479306297344"], "author_id": "24261916", "lang": "en", "id": "1600187479306297344", "conversation_id": "1600187479306297344"}, {"entities": {"mentions": [{"start": 3, "end": 14, "username": "IMFsupport", "id": "987194570"}, {"start": 75, "end": 85, "username": "VincentRK", "id": "24261916"}, {"start": 112, "end": 123, "username": "IMFmyeloma", "id": "34340707"}], "annotations": [{"start": 45, "end": 48, "probability": 0.5248, "type": "Other", "normalized_text": "NDMM"}, {"start": 87, "end": 91, "probability": 0.5779, "type": "Other", "normalized_text": "ASH22"}, {"start": 94, "end": 101, "probability": 0.6962, "type": "Other", "normalized_text": "IMFASH22"}, {"start": 104, "end": 110, "probability": 0.7516, "type": "Other", "normalized_text": "myeloma"}], "hashtags": [{"start": 44, "end": 49, "tag": "NDMM"}, {"start": 86, "end": 92, "tag": "ASH22"}, {"start": 93, "end": 102, "tag": "IMFASH22"}, {"start": 103, "end": 111, "tag": "myeloma"}]}, "text": "RT @IMFsupport: So important for those with #NDMM. Retweeting and thanking @VincentRK #ASH22 #IMFASH22 #myeloma @IMFmyeloma", "source": "Twitter for iPhone", "created_at": "2022-12-06T14:30:07.000Z", "edit_history_tweet_ids": ["1600135500727197696"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600108333867929600"}], "id": "1600135500727197696", "conversation_id": "1600135500727197696"}, {"entities": {"mentions": [{"start": 3, "end": 14, "username": "IMFsupport", "id": "987194570"}, {"start": 62, "end": 72, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 22, "end": 29, "probability": 0.5208, "type": "Other", "normalized_text": "IMFASH22"}, {"start": 81, "end": 87, "probability": 0.5935, "type": "Other", "normalized_text": "myeloma"}], "hashtags": [{"start": 21, "end": 30, "tag": "IMFASH22"}, {"start": 73, "end": 79, "tag": "ASH22"}, {"start": 80, "end": 88, "tag": "myeloma"}, {"start": 89, "end": 94, "tag": "mmsm"}]}, "text": "RT @IMFsupport: Attn #IMFASH22 Support Group Leader Team from @VincentRK #ASH22 #myeloma #mmsm", "source": "Twitter for iPhone", "created_at": "2022-12-06T01:55:10.000Z", "edit_history_tweet_ids": ["1599945514375475200"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1599925919828910081"}], "id": "1599945514375475200", "conversation_id": "1599945514375475200"}, {"entities": {"mentions": [{"start": 3, "end": 16, "username": "TRyanGregory", "id": "151257881"}], "annotations": [{"start": 42, "end": 46, "probability": 0.9773, "type": "Other", "normalized_text": "COVID"}]}, "text": "RT @TRyanGregory: What we did to mitigate COVID absolutely crushed flu. And there are, for real, people with medical and scientific trainin\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-05T23:17:01.000Z", "edit_history_tweet_ids": ["1599905713781874689"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1599571804703854592"}], "id": "1599905713781874689", "conversation_id": "1599905713781874689"}, {"entities": {"mentions": [{"start": 0, "end": 16, "username": "FrancescoMaura4", "id": "1158556316576751617"}, {"start": 17, "end": 31, "username": "DrOlaLandgren", "id": "2257190339"}, {"start": 32, "end": 48, "username": "SylvesterCancer", "id": "137901227"}, {"start": 49, "end": 65, "username": "DrGarethMorgan1", "id": "1119004052476633088"}, {"start": 66, "end": 75, "username": "szusmani", "id": "83911786"}, {"start": 76, "end": 84, "username": "NBahlis", "id": "797941194944749568"}, {"start": 85, "end": 97, "username": "MoffittNews", "id": "25324110"}, {"start": 98, "end": 110, "username": "HeidelbergU", "id": "28100372"}]}, "text": "@FrancescoMaura4 @DrOlaLandgren @SylvesterCancer @DrGarethMorgan1 @szusmani @NBahlis @MoffittNews @HeidelbergU Sure. Will get back", "source": "Twitter for iPhone", "created_at": "2022-12-05T23:10:28.000Z", "edit_history_tweet_ids": ["1599904063612768262"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599888160485699584"}], "id": "1599904063612768262", "in_reply_to_user_id": "1158556316576751617", "conversation_id": "1599802164854915076"}, {"entities": {"mentions": [{"start": 0, "end": 16, "username": "FrancescoMaura4", "id": "1158556316576751617"}, {"start": 17, "end": 31, "username": "DrOlaLandgren", "id": "2257190339"}, {"start": 32, "end": 48, "username": "SylvesterCancer", "id": "137901227"}, {"start": 49, "end": 65, "username": "DrGarethMorgan1", "id": "1119004052476633088"}, {"start": 66, "end": 75, "username": "szusmani", "id": "83911786"}, {"start": 76, "end": 84, "username": "NBahlis", "id": "797941194944749568"}, {"start": 85, "end": 97, "username": "MoffittNews", "id": "25324110"}, {"start": 98, "end": 110, "username": "HeidelbergU", "id": "28100372"}]}, "text": "@FrancescoMaura4 @DrOlaLandgren @SylvesterCancer @DrGarethMorgan1 @szusmani @NBahlis @MoffittNews @HeidelbergU Amazing productivity. Send great work.", "source": "Twitter for iPhone", "created_at": "2022-12-05T21:45:21.000Z", "edit_history_tweet_ids": ["1599882644459638784"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599802164854915076"}], "id": "1599882644459638784", "in_reply_to_user_id": "1158556316576751617", "conversation_id": "1599802164854915076"}, {"entities": {"mentions": [{"start": 3, "end": 19, "username": "FrancescoMaura4", "id": "1158556316576751617"}], "annotations": [{"start": 22, "end": 28, "probability": 0.6928, "type": "Other", "normalized_text": "ASH2022"}, {"start": 99, "end": 105, "probability": 0.7255, "type": "Other", "normalized_text": "myeloma"}], "hashtags": [{"start": 21, "end": 29, "tag": "ASH2022"}]}, "text": "RT @FrancescoMaura4: #ASH2022 is approaching and our collaborative network will present 9 orals on myeloma translational research @DrOlaLan\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-05T21:45:10.000Z", "edit_history_tweet_ids": ["1599882599614160897"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1599802164854915076"}], "id": "1599882599614160897", "conversation_id": "1599882599614160897"}, {"entities": {"mentions": [{"start": 3, "end": 14, "username": "FutureDocs", "id": "18478452"}], "annotations": [{"start": 56, "end": 60, "probability": 0.5924, "type": "Other", "normalized_text": "polio"}]}, "text": "RT @FutureDocs: Seeing media coverage about measles and polio outbreaks which is just sad given it\u2019s preventable\u2026\n\nBut nothing yet about th\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-05T21:44:23.000Z", "edit_history_tweet_ids": ["1599882399533309952"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1599573348417032199"}], "id": "1599882399533309952", "conversation_id": "1599882399533309952"}], "includes": {"users": [{"id": "24261916", "name": "Vincent Rajkumar", "username": "VincentRK"}, {"id": "58006725", "name": "C\u00e9line\u00a0Gounder,\u00a0MD, ScM, FIDSA \ud83c\uddfa\ud83c\udde6", "username": "celinegounder"}, {"id": "2212735524", "name": "chadi nabhan MD, MBA, FACP", "username": "chadinabhan"}, {"id": "218351292", "name": "Diana Gonzalez", "username": "DianaGHealth"}, {"id": "1081903728", "name": "Krishna Komanduri, MD, FASTCT \ud83c\uddfa\ud83c\udde6", "username": "drkomanduri"}, {"id": "363459113", "name": "Mary Theobald", "username": "MaryTheobald"}, {"id": "262835058", "name": "CCO Education", "username": "CCO_Education"}, {"id": "1600232317343203329", "name": "MunshiNC", "username": "MunshiNc"}, {"id": "3497730012", "name": "barttels", "username": "barttels2"}, {"id": "32760936", "name": "Jonathan Keats, PhD", "username": "PedalheadPHX"}, {"id": "2170278304", "name": "ABQ Runner", "username": "wangyub"}, {"id": "626650397", "name": "Michael Slade, MD", "username": "MichaelJSlade"}, {"id": "83911786", "name": "Saad Z. Usmani MD MBA FACP (he/his/him)\ud83c\uddfa\ud83c\uddf8\ud83c\uddf5\ud83c\uddf0", "username": "szusmani"}, {"id": "1011728551647817729", "name": "Space Force", "username": "SpaceFo25925369"}, {"id": "1365049914674266116", "name": "Turab J Mohammed, MD", "username": "DrTJM_MD"}, {"id": "2429552622", "name": "Naveen Pemmaraju, MD", "username": "doctorpemm"}, {"id": "1158556316576751617", "name": "Francesco Maura", "username": "FrancescoMaura4"}], "tweets": [{"entities": {"mentions": [{"start": 47, "end": 57, "username": "GrantWahl", "id": "36623013"}], "urls": [{"start": 151, "end": 174, "url": "https://t.co/OB3IzOxGlE", "expanded_url": "https://twitter.com/ussoccer/status/1601401947692863489", "display_url": "twitter.com/ussoccer/statu\u2026"}]}, "text": "I am so thankful for the support of my husband @GrantWahl's soccer family &amp; of so many friends who've reached out tonight.\n\nI'm in complete shock. https://t.co/OB3IzOxGlE", "source": "Twitter Web App", "created_at": "2022-12-10T02:33:34.000Z", "edit_history_tweet_ids": ["1601404727014879232"], "author_id": "58006725", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1601401947692863489"}], "id": "1601404727014879232", "conversation_id": "1601404727014879232"}, {"entities": {"mentions": [{"start": 25, "end": 35, "username": "VincentRK", "id": "24261916"}, {"start": 36, "end": 51, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 52, "end": 64, "username": "JatinShahMD", "id": "221642631"}, {"start": 181, "end": 196, "username": "ASH_hematology", "id": "84072624"}], "urls": [{"start": 250, "end": 273, "url": "https://t.co/34m8cJmQeI", "expanded_url": "https://twitter.com/chadinabhan/status/1601409465948872704/photo/1", "display_url": "pic.twitter.com/34m8cJmQeI", "media_key": "3_1601409377763790850"}], "hashtags": [{"start": 197, "end": 203, "tag": "ASH22"}, {"start": 222, "end": 229, "tag": "ASCO23"}]}, "text": "Great to spend time with @VincentRK @AaronGoodman33 @JatinShahMD and Dr. Park (not of twitter; we are trying) speaking with fellows about career paths and opportunities. Right here @ASH_hematology #ASH22 \n\nAnother program #ASCO23 ASCO being planned. https://t.co/34m8cJmQeI", "source": "Twitter for iPhone", "created_at": "2022-12-10T02:52:24.000Z", "edit_history_tweet_ids": ["1601409465948872704"], "author_id": "2212735524", "lang": "en", "id": "1601409465948872704", "conversation_id": "1601409465948872704"}, {"entities": {"mentions": [{"start": 14, "end": 29, "username": "ASH_hematology", "id": "84072624"}, {"start": 42, "end": 57, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 64, "end": 74, "username": "VincentRK", "id": "24261916"}], "urls": [{"start": 163, "end": 186, "url": "https://t.co/meTuqRdRda", "expanded_url": "https://twitter.com/chadinabhan/status/1601400573555019776/photo/1", "display_url": "pic.twitter.com/meTuqRdRda", "media_key": "3_1601400455678001152"}], "hashtags": [{"start": 30, "end": 36, "tag": "ASH22"}]}, "text": "Right here at @ASH_hematology #ASH22 with @AaronGoodman33 &amp; @VincentRK discussing science, mentorship, and music. \n\nGreat fellowship mentorship program today. https://t.co/meTuqRdRda", "source": "Twitter for iPhone", "created_at": "2022-12-10T02:17:03.000Z", "edit_history_tweet_ids": ["1601400573555019776"], "author_id": "2212735524", "lang": "en", "id": "1601400573555019776", "conversation_id": "1601400573555019776"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}, {"start": 11, "end": 24, "username": "DianaGHealth", "id": "218351292"}, {"start": 25, "end": 37, "username": "drkomanduri", "id": "1081903728"}], "annotations": [{"start": 38, "end": 44, "probability": 0.6581, "type": "Person", "normalized_text": "Vincent"}]}, "text": "@VincentRK @DianaGHealth @drkomanduri Vincent meets only if his podcaster is with him.  I\u2019m in .", "source": "Twitter for iPhone", "created_at": "2022-12-10T00:27:00.000Z", "edit_history_tweet_ids": ["1601372875193081856"], "author_id": "2212735524", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601364514083307520"}], "id": "1601372875193081856", "in_reply_to_user_id": "24261916", "conversation_id": "1601361416644362240"}, {"text": "Except for slight modifications expanding  DRd options in frontline after discussion with colleagues on the panel today, this is essentially same as what I posted a few days ago.", "source": "Twitter for iPhone", "created_at": "2022-12-10T00:36:18.000Z", "edit_history_tweet_ids": ["1601375218513375232"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601372656707649536"}], "id": "1601375218513375232", "in_reply_to_user_id": "24261916", "conversation_id": "1601372628232851456"}, {"text": "5. Smoldering myeloma. For the one third who meet criteria for high risk smoldering myeloma, recommend therapy with  Len or Len/Dex for 2 years or clinical trial. #ASH22 https://t.co/XUKxCngyT6", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 14, "end": 20, "probability": 0.5789, "type": "Other", "normalized_text": "myeloma"}, {"start": 84, "end": 90, "probability": 0.5639, "type": "Other", "normalized_text": "myeloma"}, {"start": 117, "end": 119, "probability": 0.7411, "type": "Other", "normalized_text": "Len"}, {"start": 124, "end": 126, "probability": 0.7029, "type": "Other", "normalized_text": "Len"}, {"start": 128, "end": 130, "probability": 0.5914, "type": "Other", "normalized_text": "Dex"}, {"start": 164, "end": 168, "probability": 0.4756, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 170, "end": 193, "url": "https://t.co/XUKxCngyT6", "expanded_url": "https://twitter.com/VincentRK/status/1601372656707649536/photo/1", "display_url": "pic.twitter.com/XUKxCngyT6", "media_key": "3_1601372651989213189"}], "hashtags": [{"start": 163, "end": 169, "tag": "ASH22"}]}, "created_at": "2022-12-10T00:26:08.000Z", "edit_history_tweet_ids": ["1601372656707649536"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601372649598648320"}], "id": "1601372656707649536", "in_reply_to_user_id": "24261916", "conversation_id": "1601372628232851456"}, {"text": "4. Second on higher  relapse. Try one of the first relapse regimens that the patient is not refractory to. #ASH22 \n\nTriple refractory: Either alkylator or BCMA targeted therapy. \n\nBCMA refractory options also listed below. https://t.co/3dfjHxAQha", "source": "Twitter for iPhone", "entities": {"urls": [{"start": 223, "end": 246, "url": "https://t.co/3dfjHxAQha", "expanded_url": "https://twitter.com/VincentRK/status/1601372649598648320/photo/1", "display_url": "pic.twitter.com/3dfjHxAQha", "media_key": "3_1601372645341253633"}], "hashtags": [{"start": 107, "end": 113, "tag": "ASH22"}]}, "created_at": "2022-12-10T00:26:06.000Z", "edit_history_tweet_ids": ["1601372649598648320"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601372642866761728"}], "id": "1601372649598648320", "in_reply_to_user_id": "24261916", "conversation_id": "1601372628232851456"}, {"text": "3. First relapse. The approach depends on refractoriness to Len and CD38moAB. For CD38 Moab either Daratumumab or Isatuximab are OK. Depends on cost and availability. #ASH22 https://t.co/Nw0afMaOxF", "source": "Twitter for iPhone", "entities": {"urls": [{"start": 174, "end": 197, "url": "https://t.co/Nw0afMaOxF", "expanded_url": "https://twitter.com/VincentRK/status/1601372642866761728/photo/1", "display_url": "pic.twitter.com/Nw0afMaOxF", "media_key": "3_1601372639175524353"}], "hashtags": [{"start": 167, "end": 173, "tag": "ASH22"}]}, "created_at": "2022-12-10T00:26:04.000Z", "edit_history_tweet_ids": ["1601372642866761728"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601372636268765187"}], "id": "1601372642866761728", "in_reply_to_user_id": "24261916", "conversation_id": "1601372628232851456"}, {"text": "2. Newly Diagnosed myeloma transplant eligible. #ASH22\n\nEarly transplant preferred. But for selected standard risk patients depending on preference, delayed is also OK. Maintenance varies by risk stratification. https://t.co/pfV83LhB5R", "source": "Twitter for iPhone", "entities": {"urls": [{"start": 212, "end": 235, "url": "https://t.co/pfV83LhB5R", "expanded_url": "https://twitter.com/VincentRK/status/1601372636268765187/photo/1", "display_url": "pic.twitter.com/pfV83LhB5R", "media_key": "3_1601372631135035395"}], "hashtags": [{"start": 48, "end": 54, "tag": "ASH22"}]}, "created_at": "2022-12-10T00:26:03.000Z", "edit_history_tweet_ids": ["1601372636268765187"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601372628232851456"}], "id": "1601372636268765187", "in_reply_to_user_id": "24261916", "conversation_id": "1601372628232851456"}, {"entities": {"mentions": [{"start": 50, "end": 61, "username": "IMFmyeloma", "id": "34340707"}, {"start": 62, "end": 76, "username": "CCO_Education", "id": "262835058"}], "annotations": [{"start": 8, "end": 14, "probability": 0.6613, "type": "Other", "normalized_text": "Myeloma"}, {"start": 26, "end": 35, "probability": 0.4109, "type": "Other", "normalized_text": "Algorithms"}, {"start": 98, "end": 102, "probability": 0.5436, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 216, "end": 239, "url": "https://t.co/GlniXt6h5q", "expanded_url": "https://twitter.com/VincentRK/status/1601372628232851456/photo/1", "display_url": "pic.twitter.com/GlniXt6h5q", "media_key": "3_1601372624642351109"}], "hashtags": [{"start": 97, "end": 103, "tag": "ASH22"}]}, "text": "Updated Myeloma Treatment Algorithms presented at @IMFmyeloma @CCO_Education symposium  today at #ASH22 \n\n1. Newly diagnosed transplant ineligible. Either VRd or DRd is OK. Maintenance varies by risk stratification. https://t.co/GlniXt6h5q", "source": "Twitter for iPhone", "created_at": "2022-12-10T00:26:01.000Z", "edit_history_tweet_ids": ["1601372628232851456"], "author_id": "24261916", "lang": "en", "id": "1601372628232851456", "conversation_id": "1601372628232851456"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "drkomanduri", "id": "1081903728"}, {"start": 13, "end": 23, "username": "VincentRK", "id": "24261916"}]}, "text": "@drkomanduri @VincentRK Twitter friends! Please post those meet-up.", "source": "Twitter for iPhone", "created_at": "2022-12-09T23:53:25.000Z", "edit_history_tweet_ids": ["1601364427093123072"], "author_id": "218351292", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601362946294435841"}], "id": "1601364427093123072", "in_reply_to_user_id": "1081903728", "conversation_id": "1601361416644362240"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}]}, "text": "@VincentRK Would love to see you Vince. Amazing we have never met in person.", "source": "Twitter for iPhone", "created_at": "2022-12-09T23:47:32.000Z", "edit_history_tweet_ids": ["1601362946294435841"], "author_id": "1081903728", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601362468395094016"}], "id": "1601362946294435841", "in_reply_to_user_id": "24261916", "conversation_id": "1601361416644362240"}, {"text": "I believe #CafeDuMonde should sell shirts that say \u201cIt\u2019s not cocaine\u2014I just had beignets at Cafe Du Monde.\u201d \n\nWho else would buy one?", "source": "Twitter for iPhone", "created_at": "2022-12-09T23:41:28.000Z", "edit_history_tweet_ids": ["1601361416644362240"], "author_id": "1081903728", "lang": "en", "entities": {"hashtags": [{"start": 10, "end": 22, "tag": "CafeDuMonde"}]}, "id": "1601361416644362240", "conversation_id": "1601361416644362240"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}, {"start": 11, "end": 26, "username": "SandyWong02111", "id": "4050824739"}, {"start": 27, "end": 38, "username": "ninashah33", "id": "1559241414"}, {"start": 39, "end": 55, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 56, "end": 66, "username": "TomBmt133", "id": "812851718014701568"}]}, "text": "@VincentRK @SandyWong02111 @ninashah33 @RahulBanerjeeMD @TomBmt133 What's the median time to progression on/after CAR-T?", "source": "Twitter Web App", "created_at": "2022-12-09T23:36:49.000Z", "edit_history_tweet_ids": ["1601360246077022208"], "author_id": "363459113", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601235882824331267"}], "id": "1601360246077022208", "in_reply_to_user_id": "24261916", "conversation_id": "1601235882824331267"}, {"entities": {"mentions": [{"start": 4, "end": 14, "username": "VincentRK", "id": "24261916"}], "urls": [{"start": 113, "end": 136, "url": "https://t.co/9tDctPVkWk", "expanded_url": "https://twitter.com/NorthTxMSG/status/1601287835507490817/photo/1", "display_url": "pic.twitter.com/9tDctPVkWk", "media_key": "3_1601287142985977856"}, {"start": 113, "end": 136, "url": "https://t.co/9tDctPVkWk", "expanded_url": "https://twitter.com/NorthTxMSG/status/1601287835507490817/photo/1", "display_url": "pic.twitter.com/9tDctPVkWk", "media_key": "3_1601287155942248448"}, {"start": 137, "end": 160, "url": "https://t.co/8M23TSx7oR", "expanded_url": "https://twitter.com/NorthTxMSG/status/1601283697356943360", "display_url": "twitter.com/NorthTxMSG/sta\u2026"}], "hashtags": [{"start": 79, "end": 85, "tag": "ASH22"}, {"start": 86, "end": 91, "tag": "mmsm"}]}, "text": "Dr. @VincentRK introducing his TRAP treatment selection acronym as part of his #ASH22 #mmsm treatment algorithm. https://t.co/9tDctPVkWk https://t.co/8M23TSx7oR", "source": "Twitter Web App", "created_at": "2022-12-09T18:49:05.000Z", "edit_history_tweet_ids": ["1601287835507490817"], "author_id": "961409220", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1601283697356943360"}], "id": "1601287835507490817", "conversation_id": "1601287835507490817"}, {"entities": {"mentions": [{"start": 59, "end": 73, "username": "CCO_Education", "id": "262835058"}, {"start": 76, "end": 87, "username": "IMFmyeloma", "id": "34340707"}, {"start": 108, "end": 118, "username": "myelomaMD", "id": "301568235"}, {"start": 121, "end": 132, "username": "YiLinMDPhD", "id": "1325894012"}, {"start": 135, "end": 145, "username": "VincentRK", "id": "24261916"}, {"start": 169, "end": 179, "username": "TomBmt133", "id": "812851718014701568"}], "annotations": [{"start": 23, "end": 27, "probability": 0.519, "type": "Other", "normalized_text": "ASH22"}, {"start": 49, "end": 55, "probability": 0.6284, "type": "Other", "normalized_text": "myeloma"}, {"start": 84, "end": 96, "probability": 0.8652, "type": "Person", "normalized_text": "oma\u2069 \nPhilipp"}, {"start": -1, "end": 144, "probability": 0.4873, "type": "Other", "normalized_text": "\ufffd\ufffd \u2066@VincentRK"}], "urls": [{"start": 181, "end": 204, "url": "https://t.co/bzaNNS2WjF", "expanded_url": "https://twitter.com/myelomaMD/status/1601263313320542209/photo/1", "display_url": "pic.twitter.com/bzaNNS2WjF", "media_key": "3_1601263307129856001"}], "hashtags": [{"start": 22, "end": 28, "tag": "ASH22"}]}, "text": "We are about to start #ASH22 Friday symposium on myeloma. \u2066@CCO_Education\u2069 \u2066@IMFmyeloma\u2069 \nPhilippe Moreau, \u2066@myelomaMD\u2069 \u2066@YiLinMDPhD\u2069 \u2066@VincentRK\u2069 Jesus San Miguel and \u2066@TomBmt133\u2069 https://t.co/bzaNNS2WjF", "source": "Twitter for iPhone", "created_at": "2022-12-09T17:11:38.000Z", "edit_history_tweet_ids": ["1601263313320542209"], "author_id": "301568235", "lang": "en", "id": "1601263313320542209", "conversation_id": "1601263313320542209"}, {"entities": {"mentions": [{"start": 23, "end": 33, "username": "myelomaMD", "id": "301568235"}], "annotations": [{"start": 74, "end": 79, "probability": 0.6945, "type": "Other", "normalized_text": "ASCENT"}, {"start": 142, "end": 148, "probability": 0.6294, "type": "Other", "normalized_text": "myeloma"}, {"start": 233, "end": 239, "probability": 0.5548, "type": "Other", "normalized_text": "myeloma"}], "urls": [{"start": 248, "end": 271, "url": "https://t.co/9fvVoPvwBM", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168930.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Risk-adapted Treatment Strategies in Myeloma and Related Conditions Hematology Disease Topics & Pathways: Research, clinical trials, Biological therapies, Antibody Therapy, Clinical Research, Plasma Cell Disorders, Combination therapy, Diseases, Therapies, Lymphoid Malignancies, Human, Minimal Residual Disease Shaji K Kumar, MD 1, Melissa Alsina, MD** 2, Betsy Laplant, MS 3 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168930.html"}, {"start": 272, "end": 295, "url": "https://t.co/GXdvY4J72z", "expanded_url": "https://twitter.com/VincentRK/status/1600900413330374657/photo/1", "display_url": "pic.twitter.com/GXdvY4J72z", "media_key": "3_1600900401452257285"}], "hashtags": [{"start": 3, "end": 9, "tag": "ASH22"}]}, "text": "At #ASH22 my colleague @myelomaMD will present the initial results of the ASCENT trial, aka the 2nd Cure trial to test the hypothesis whether myeloma can be cured if highly active combination therapy is given early at the smoldering myeloma stage. https://t.co/9fvVoPvwBM https://t.co/GXdvY4J72z", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:09:36.000Z", "edit_history_tweet_ids": ["1600900413330374657"], "author_id": "24261916", "lang": "en", "id": "1600900413330374657", "conversation_id": "1600900413330374657"}, {"text": "Probably also in part reflects the patient selection for CAR-T. #ASH22", "source": "Twitter for iPhone", "created_at": "2022-12-09T15:22:39.000Z", "edit_history_tweet_ids": ["1601235886477545472"], "author_id": "24261916", "lang": "en", "entities": {"hashtags": [{"start": 64, "end": 70, "tag": "ASH22"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1601235882824331267"}], "id": "1601235886477545472", "in_reply_to_user_id": "24261916", "conversation_id": "1601235882824331267"}, {"entities": {"mentions": [{"start": 179, "end": 194, "username": "SandyWong02111", "id": "4050824739"}, {"start": 195, "end": 206, "username": "ninashah33", "id": "1559241414"}, {"start": 207, "end": 223, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 224, "end": 234, "username": "TomBmt133", "id": "812851718014701568"}], "annotations": [{"start": 11, "end": 15, "probability": 0.5514, "type": "Other", "normalized_text": "CAR-T"}, {"start": 20, "end": 26, "probability": 0.6062, "type": "Other", "normalized_text": "myeloma"}, {"start": 30, "end": 34, "probability": 0.5962, "type": "Other", "normalized_text": "ASH22"}, {"start": 101, "end": 105, "probability": 0.6813, "type": "Other", "normalized_text": "CAR-T"}, {"start": 168, "end": 177, "probability": 0.7291, "type": "Person", "normalized_text": "KevinReyes"}], "urls": [{"start": 235, "end": 258, "url": "https://t.co/IxU6jcxOGH", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper160401.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy", "description": "Progra m: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Relapsed and/or Refractory Myeloma (RRMM) Hematology Disease Topics & Pathways: Research, Biological therapies, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Clinical Research, health outcomes research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Immunotherapy, therapy sequence, Lymphoid", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper160401.html"}, {"start": 259, "end": 282, "url": "https://t.co/tHEheouRHm", "expanded_url": "https://twitter.com/VincentRK/status/1601235882824331267/photo/1", "display_url": "pic.twitter.com/tHEheouRHm", "media_key": "3_1601235876239097856"}], "hashtags": [{"start": 29, "end": 35, "tag": "ASH22"}, {"start": 167, "end": 178, "tag": "KevinReyes"}]}, "text": "Life after CAR-T in myeloma. #ASH22 abstract shows median survival of 15 months after progression on CAR-T. \n\nIndicates that we have options for therapy post CAR-T. \n\n#KevinReyes @SandyWong02111 @ninashah33 @RahulBanerjeeMD @TomBmt133 https://t.co/IxU6jcxOGH https://t.co/tHEheouRHm", "source": "Twitter for iPhone", "created_at": "2022-12-09T15:22:38.000Z", "edit_history_tweet_ids": ["1601235882824331267"], "author_id": "24261916", "lang": "en", "id": "1601235882824331267", "conversation_id": "1601235882824331267"}, {"entities": {"mentions": [{"start": 129, "end": 139, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 47, "end": 53, "probability": 0.651, "type": "Other", "normalized_text": "Myeloma"}, {"start": 56, "end": 83, "probability": 0.7331, "type": "Other", "normalized_text": "Evolving Treatment Landscape"}, {"start": 91, "end": 93, "probability": 0.3976, "type": "Organization", "normalized_text": "IMF"}, {"start": 97, "end": 109, "probability": 0.6309, "type": "Other", "normalized_text": "HYATT REGENCY"}, {"start": 114, "end": 120, "probability": 0.8098, "type": "Other", "normalized_text": "ELITE B"}], "urls": [{"start": 160, "end": 183, "url": "https://t.co/DAZB6aqeVo", "expanded_url": "https://loom.ly/VderfLM", "display_url": "loom.ly/VderfLM", "status": 200, "title": "Myeloma | CCO Free CE/CME Event", "description": "LOCATION: Hyatt Regency New Orleans 601 Loyola Ave Room: Elite B New Orleans, LA 70113 Hyatt Regency New Orleans 601 Loyola Ave Room: Elite B New Orleans, LA 70113 Get Directions Clinical Care Options, LLC. is committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to", "unwound_url": "https://pages.mycea.com/event-3-hematology-december-2022.html?utm_source=twitter&utm_medium=social&utm_campaign=ASH-2022-organic-social&utm_content=&utm_term="}], "hashtags": [{"start": 13, "end": 21, "tag": "ASH2022"}]}, "text": "11AM CT Pre- #ASH2022 Friday Session Reminder! Myeloma: Evolving Treatment Landscape, with IMF @ HYATT REGENCY in ELITE B, feat. @VincentRK &amp; other experts https://t.co/DAZB6aqeVo", "source": "Loomly", "created_at": "2022-12-09T15:03:32.000Z", "edit_history_tweet_ids": ["1601231076378148866"], "author_id": "262835058", "lang": "en", "id": "1601231076378148866", "conversation_id": "1601231076378148866"}, {"entities": {"mentions": [{"start": 35, "end": 45, "username": "VincentRK", "id": "24261916"}, {"start": 46, "end": 56, "username": "myelomaMD", "id": "301568235"}], "annotations": [{"start": 12, "end": 16, "probability": 0.4931, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 257, "end": 280, "url": "https://t.co/1M00p1o0Po", "expanded_url": "https://ashpublications.org/blood/article/140/Supplement%201/9998/490520/Outcomes-of-Multiple-Myeloma-Patients-Refractory?s=03", "display_url": "ashpublications.org/blood/article/\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600930662206144512/HlLocYUP?format=png&name=orig", "width": 520, "height": 709}, {"url": "https://pbs.twimg.com/news_img/1600930662206144512/HlLocYUP?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide", "description": "Background: Lenalidomide (Len) containing regimens are extensively used as first line therapy in multiple myeloma (MM). Since most patients (pts) eventually rel", "unwound_url": "https://ashpublications.org/blood/article/140/Supplement%201/9998/490520/Outcomes-of-Multiple-Myeloma-Patients-Refractory?s=03"}, {"start": 281, "end": 304, "url": "https://t.co/T7OcZrMFPf", "expanded_url": "https://twitter.com/majorajay/status/1600930651233931264/photo/1", "display_url": "pic.twitter.com/T7OcZrMFPf", "media_key": "3_1600929871408074770"}], "hashtags": [{"start": 11, "end": 17, "tag": "ASH22"}, {"start": 250, "end": 255, "tag": "mmsm"}]}, "text": "Phenomenal #ASH22 abstract by Drs. @VincentRK @myelomaMD et al. on a question I got every week as a myeloma fellow by patients with progression through len: \"Can't we just increase the dose?\" Appears that len refractory status is not dose dependent. #mmsm\n\nhttps://t.co/1M00p1o0Po https://t.co/T7OcZrMFPf", "source": "Twitter Web App", "created_at": "2022-12-08T19:09:45.000Z", "edit_history_tweet_ids": ["1600930651233931264"], "author_id": "409755591", "lang": "en", "id": "1600930651233931264", "conversation_id": "1600930651233931264"}, {"entities": {"mentions": [{"start": 68, "end": 78, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 4, "end": 8, "probability": 0.6304, "type": "Other", "normalized_text": "ASH22"}, {"start": 51, "end": 62, "probability": 0.9573, "type": "Person", "normalized_text": "Ken Anderson"}], "urls": [{"start": 79, "end": 102, "url": "https://t.co/rAmJkei5QW", "expanded_url": "https://twitter.com/MunshiNc/status/1601055876286058496/photo/1", "display_url": "pic.twitter.com/rAmJkei5QW", "media_key": "3_1601055869348843523"}], "hashtags": [{"start": 3, "end": 9, "tag": "ASH22"}]}, "text": "At #ASH22. MY first tweet with my 2 best friends ! Ken Anderson and @VincentRK https://t.co/rAmJkei5QW", "source": "Twitter for Android", "created_at": "2022-12-09T03:27:21.000Z", "edit_history_tweet_ids": ["1601055876286058496"], "author_id": "1600232317343203329", "lang": "en", "id": "1601055876286058496", "conversation_id": "1601055876286058496"}, {"text": "Why do you attend large medical meetings these days? #MedTwitter #ASH22\n\nIf other, add comment.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 54, "end": 63, "probability": 0.8911, "type": "Other", "normalized_text": "MedTwitter"}, {"start": 66, "end": 70, "probability": 0.5836, "type": "Other", "normalized_text": "ASH22"}], "hashtags": [{"start": 53, "end": 64, "tag": "MedTwitter"}, {"start": 65, "end": 71, "tag": "ASH22"}]}, "created_at": "2022-12-08T13:54:32.000Z", "edit_history_tweet_ids": ["1600851323590680577"], "author_id": "24261916", "lang": "en", "id": "1600851323590680577", "conversation_id": "1600851323590680577"}, {"entities": {"mentions": [{"start": 7, "end": 17, "username": "VincentRK", "id": "24261916"}, {"start": 129, "end": 137, "username": "OncLive", "id": "43051682"}], "annotations": [{"start": 1, "end": 5, "probability": 0.5148, "type": "Other", "normalized_text": "ASH22"}, {"start": 42, "end": 52, "probability": 0.5213, "type": "Other", "normalized_text": "Elranatamab"}], "urls": [{"start": 101, "end": 124, "url": "https://t.co/c2v8EZ6nJZ", "expanded_url": "https://www.onclive.com/view/rajkumar-previews-car-t-updates-elranatamab-findings-in-multiple-myeloma-ahead-of-ash-2022", "display_url": "onclive.com/view/rajkumar-\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600948432784465923/Xxb0gnBH?format=jpg&name=orig", "width": 200, "height": 200}, {"url": "https://pbs.twimg.com/news_img/1600948432784465923/Xxb0gnBH?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022", "description": "S. Vincent Rajkumar, MD, previews his top 5 abstracts in multiple myeloma ahead of the 2022 ASH Annual Meeting.", "unwound_url": "https://www.onclive.com/view/rajkumar-previews-car-t-updates-elranatamab-findings-in-multiple-myeloma-ahead-of-ash-2022"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}]}, "text": "#ASH22 @VincentRK Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022 https://t.co/c2v8EZ6nJZ via @onclive", "source": "Twitter for iPhone", "created_at": "2022-12-08T22:01:14.000Z", "edit_history_tweet_ids": ["1600973804129648642"], "author_id": "1407780158", "lang": "en", "id": "1600973804129648642", "conversation_id": "1600973804129648642"}, {"entities": {"mentions": [{"start": 225, "end": 233, "username": "nytimes", "id": "807095"}, {"start": 239, "end": 246, "username": "snolen", "id": "21882251"}], "annotations": [{"start": 164, "end": 168, "probability": 0.8991, "type": "Other", "normalized_text": "Covax"}], "urls": [{"start": 249, "end": 272, "url": "https://t.co/YctRKejICo", "expanded_url": "https://www.nytimes.com/2022/12/06/health/covid-vaccines-covax-gavi.html?referringSource=articleShare", "display_url": "nytimes.com/2022/12/06/hea\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600387200281374721/AeagPT7y?format=jpg&name=orig", "width": 3000, "height": 1688}, {"url": "https://pbs.twimg.com/news_img/1600387200281374721/AeagPT7y?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Global Partners May End Broad Covid Vaccination Effort in Developing Countries", "description": "The board of Gavi, the international vaccine agency, meets Wednesday to debate shutting down the program, known as Covax, amid swiftly waning demand for the shots.", "unwound_url": "https://www.nytimes.com/2022/12/06/health/covid-vaccines-covax-gavi.html?referringSource=articleShare"}]}, "text": "The global vax campaign is far more unequal today than it was earlier in the pandemic. \n\nBooster momentum is close to 0 in developing countries. \n\nAmidst all this, Covax may be shut down. \n\nIs it the right time?\n\nMy words in @nytimes with @snolen.  https://t.co/YctRKejICo", "source": "Twitter for iPhone", "created_at": "2022-12-07T07:39:19.000Z", "edit_history_tweet_ids": ["1600394509623386112"], "author_id": "237899667", "lang": "en", "id": "1600394509623386112", "conversation_id": "1600394509623386112"}, {"entities": {"mentions": [{"start": 92, "end": 102, "username": "VincentRK", "id": "24261916"}, {"start": 103, "end": 118, "username": "MayoCancerCare", "id": "2396756364"}, {"start": 119, "end": 134, "username": "ASH_hematology", "id": "84072624"}], "annotations": [{"start": 0, "end": 7, "probability": 0.5528, "type": "Person", "normalized_text": "Rajkumar"}, {"start": 33, "end": 43, "probability": 0.542, "type": "Other", "normalized_text": "Elranatamab"}], "urls": [{"start": 148, "end": 171, "url": "https://t.co/vfIT739rJT", "expanded_url": "http://ow.ly/nzwb50LYSnu", "display_url": "ow.ly/nzwb50LYSnu", "images": [{"url": "https://pbs.twimg.com/news_img/1600948432784465923/Xxb0gnBH?format=jpg&name=orig", "width": 200, "height": 200}, {"url": "https://pbs.twimg.com/news_img/1600948432784465923/Xxb0gnBH?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022", "description": "S. Vincent Rajkumar, MD, previews his top 5 abstracts in multiple myeloma ahead of the 2022 ASH Annual Meeting.", "unwound_url": "https://www.onclive.com/view/rajkumar-previews-car-t-updates-elranatamab-findings-in-multiple-myeloma-ahead-of-ash-2022"}], "hashtags": [{"start": 135, "end": 141, "tag": "ASH22"}, {"start": 142, "end": 147, "tag": "mmsm"}]}, "text": "Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022 @VincentRK @MayoCancerCare @ASH_hematology #ASH22 #mmsm https://t.co/vfIT739rJT", "source": "Hootsuite Inc.", "created_at": "2022-12-08T20:20:24.000Z", "edit_history_tweet_ids": ["1600948429877907456"], "author_id": "43051682", "lang": "en", "id": "1600948429877907456", "conversation_id": "1600948429877907456"}, {"entities": {"mentions": [{"start": 166, "end": 180, "username": "IreneGhobrial", "id": "452461489"}, {"start": 185, "end": 199, "username": "DrOlaLandgren", "id": "2257190339"}], "annotations": [{"start": 90, "end": 92, "probability": 0.6869, "type": "Other", "normalized_text": "SMM"}]}, "text": "I must say many leaders in the field share the same vision and commitment with regards to SMM. And are doing a range of studies and trials in this regard, especially @IreneGhobrial and @DrOlaLandgren \n\nThe full spectrum of studies is what it will take to solve this puzzle.", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:47:51.000Z", "edit_history_tweet_ids": ["1600910040931520512"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600904751147003904"}], "id": "1600910040931520512", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"entities": {"mentions": [{"start": 60, "end": 73, "username": "DeVitaDoctor", "id": "50178358"}], "annotations": [{"start": 104, "end": 119, "probability": 0.7154, "type": "Other", "normalized_text": "Hodgkin lymphoma"}]}, "text": "We have the same vision and goal. For me it was inspired by @DeVitaDoctor and how he approached cure in Hodgkin lymphoma: Cure means fixed duration therapy, stop treatment, the disease never ever comes back in a reasonable proportion of patients.  \n\nThat\u2019s what we are going for.", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:26:50.000Z", "edit_history_tweet_ids": ["1600904751147003904"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600903774326833153"}], "id": "1600904751147003904", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}, {"start": 11, "end": 24, "username": "DeVitaDoctor", "id": "50178358"}], "annotations": [{"start": 55, "end": 73, "probability": 0.9825, "type": "Other", "normalized_text": "The Death of Cancer"}]}, "text": "@VincentRK @DeVitaDoctor I believe I\u2019ve mentioned that The Death of Cancer is my favorite book on the subject. Definitely also the most fearless and most fun.", "source": "Twitter for iPad", "created_at": "2022-12-08T17:41:46.000Z", "edit_history_tweet_ids": ["1600908510178738177"], "author_id": "3497730012", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600904751147003904"}], "id": "1600908510178738177", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"entities": {"mentions": [{"start": 118, "end": 127, "username": "mvmateos", "id": "2239926566"}, {"start": 132, "end": 142, "username": "myelomaMD", "id": "301568235"}]}, "text": "This is a multi decade vision. I\u2019m glad the trials were started and we already have years of follow up. \n\nCongrats to @mvmateos and @myelomaMD for overcoming numerous obstacles to get us to this point.", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:22:57.000Z", "edit_history_tweet_ids": ["1600903774326833153"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600903255004831744"}], "id": "1600903774326833153", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"entities": {"mentions": [{"start": 177, "end": 192, "username": "ASH_hematology", "id": "84072624"}], "annotations": [{"start": 65, "end": 67, "probability": 0.7525, "type": "Other", "normalized_text": "MRD"}, {"start": 171, "end": 175, "probability": 0.4795, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 193, "end": 216, "url": "https://t.co/b6P5onvY5g", "expanded_url": "https://twitter.com/vincentrk/status/1600901502654361600", "display_url": "twitter.com/vincentrk/stat\u2026"}], "hashtags": [{"start": 170, "end": 176, "tag": "ASH22"}]}, "text": "I love the fact that this is a fixed duration study and explores MRD. I believe curing a disease requires eradication at the molecular level. Trials will determine that. #ASH22 @ASH_hematology https://t.co/b6P5onvY5g", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:15:53.000Z", "edit_history_tweet_ids": ["1600901994658418688"], "author_id": "2212735524", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600901502654361600"}], "id": "1600901994658418688", "conversation_id": "1600901994658418688"}, {"text": "There will be successor trials similar to CESAR and ASCENT. If and when the results look very promising the next step would be to compare the winning regimen from one of the Cure trials to whatever is standard of care at the time in a randomized trial.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 42, "end": 46, "probability": 0.3215, "type": "Person", "normalized_text": "CESAR"}, {"start": 52, "end": 57, "probability": 0.5336, "type": "Other", "normalized_text": "ASCENT"}]}, "created_at": "2022-12-08T17:20:53.000Z", "edit_history_tweet_ids": ["1600903255004831744"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600902726778589211"}], "id": "1600903255004831744", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"text": "It will be a decade or two to determine whether we are successful. The natural history of high risk SMM with observation or mild therapy is known. The goal with the Cure trials is to see if there is a plateau in disease free survival that\u2019s enduring &amp; far beyond what\u2019s expected.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 100, "end": 102, "probability": 0.7741, "type": "Other", "normalized_text": "SMM"}, {"start": 165, "end": 168, "probability": 0.696, "type": "Other", "normalized_text": "Cure"}]}, "created_at": "2022-12-08T17:18:48.000Z", "edit_history_tweet_ids": ["1600902726778589211"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600901502654361600"}], "id": "1600902726778589211", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"text": "These trials are part of a planned series of trials investigating whether the incurability of myeloma is related to the fact that we have traditionally started effective therapy only after the disease has spread and mutated to the point where it is no longer curable.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 94, "end": 100, "probability": 0.7607, "type": "Other", "normalized_text": "myeloma"}]}, "created_at": "2022-12-08T17:13:56.000Z", "edit_history_tweet_ids": ["1600901502654361600"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600901116744851458"}], "id": "1600901502654361600", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"entities": {"mentions": [{"start": 58, "end": 67, "username": "mvmateos", "id": "2239926566"}], "annotations": [{"start": 45, "end": 49, "probability": 0.3582, "type": "Organization", "normalized_text": "CESAR"}, {"start": 96, "end": 100, "probability": 0.4999, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 103, "end": 126, "url": "https://t.co/RAdqP5Dfl0", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Minimal Residual Disease Maria-Victoria Mateos, MD 1, Joaqu\u00edn Mart\u00ednez-L\u00f3pez, MD, PhD 2 *, Paula Rodr\u00edguez-Otero, MD, PhD 3 *, Jes\u00fas San-Miguel, MD, PhD 4, Veronica Gonzalez-Calle, MD, PhD 1 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html"}], "hashtags": [{"start": 95, "end": 101, "tag": "ASH22"}]}, "text": "Updated results from the 1st Cure trial, GEM-CESAR led by @mvmateos is also being presented at #ASH22\n\nhttps://t.co/RAdqP5Dfl0", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:12:24.000Z", "edit_history_tweet_ids": ["1600901116744851458"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600900413330374657"}], "id": "1600901116744851458", "in_reply_to_user_id": "24261916", "conversation_id": "1600900413330374657"}, {"entities": {"mentions": [{"start": 25, "end": 40, "username": "ASH_hematology", "id": "84072624"}], "annotations": [{"start": 19, "end": 23, "probability": 0.5601, "type": "Other", "normalized_text": "ASH22"}, {"start": 41, "end": 47, "probability": 0.6072, "type": "Other", "normalized_text": "myeloma"}, {"start": 61, "end": 67, "probability": 0.5923, "type": "Other", "normalized_text": "ASH22VR"}], "hashtags": [{"start": 18, "end": 24, "tag": "ASH22"}, {"start": 60, "end": 68, "tag": "ASH22VR"}]}, "text": "Here are my Top 5 #ASH22 @ASH_hematology myeloma abstracts. #ASH22VR  \nLinks to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact &amp; methodology\n\nThread with countdown\ud83d\udc47", "source": "Twitter for iPhone", "created_at": "2022-12-03T16:19:18.000Z", "edit_history_tweet_ids": ["1599075814553026562"], "author_id": "24261916", "lang": "en", "id": "1599075814553026562", "conversation_id": "1599075814553026562"}, {"entities": {"mentions": [{"start": 119, "end": 129, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 47, "end": 50, "probability": 0.6487, "type": "Other", "normalized_text": "IMWG"}, {"start": 84, "end": 90, "probability": 0.5099, "type": "Other", "normalized_text": "myeloma"}], "urls": [{"start": 130, "end": 153, "url": "https://t.co/oBEMJJJedH", "expanded_url": "https://twitter.com/VincentRK/status/1600533243392057344", "display_url": "twitter.com/VincentRK/stat\u2026"}]}, "text": "Great thread to revisit and understand the The IMWG updated diagnostic criteria for myeloma &amp; related disorders by @VincentRK https://t.co/oBEMJJJedH", "source": "Twitter for iPhone", "created_at": "2022-12-08T01:25:14.000Z", "edit_history_tweet_ids": ["1600662755132207104"], "author_id": "912014667932979200", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600533243392057344"}], "id": "1600662755132207104", "conversation_id": "1600662755132207104"}, {"entities": {"mentions": [{"start": 37, "end": 52, "username": "ASH_hematology", "id": "84072624"}, {"start": 103, "end": 114, "username": "jmikhaelmd", "id": "2377190652"}]}, "text": "Second year in a row I didn\u2019t get my @ASH_hematology meeting badge in the mail. Would not compete with @jmikhaelmd on stickers but getting ripped off again", "source": "Twitter for iPhone", "created_at": "2022-12-07T23:26:20.000Z", "edit_history_tweet_ids": ["1600632832522702848"], "author_id": "32760936", "lang": "en", "id": "1600632832522702848", "conversation_id": "1600632832522702848"}, {"entities": {"mentions": [{"start": 0, "end": 8, "username": "wangyub", "id": "2170278304"}], "annotations": [{"start": 58, "end": 60, "probability": 0.5254, "type": "Other", "normalized_text": "MRI"}, {"start": 82, "end": 84, "probability": 0.415, "type": "Other", "normalized_text": "MDE"}, {"start": 181, "end": 183, "probability": 0.6077, "type": "Other", "normalized_text": "MRI"}]}, "text": "@wangyub The criteria are very specific on how to use the MRI. If that\u2019s the only MDE you need bone marrow with &gt;=10% clonal plasma cells and 2 or more definite focal lesions on MRI at least 5mm in size. If in doubt wait 3-6 months and repeat. Diffuse abnormalities or signal is not MDE.", "source": "Twitter for iPhone", "created_at": "2022-12-08T06:27:45.000Z", "edit_history_tweet_ids": ["1600738885784330242"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600720749224136704"}], "id": "1600738885784330242", "in_reply_to_user_id": "2170278304", "conversation_id": "1600533243392057344"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 14, "end": 16, "probability": 0.5607, "type": "Organization", "normalized_text": "MRI"}, {"start": 92, "end": 94, "probability": 0.6014, "type": "Other", "normalized_text": "MRI"}]}, "text": "@VincentRK Is MRI producing more false positive bone lesions? We get consult about abnormal MRI bone marrow signals quite often and rarely showed any positive findings on biopsy.", "source": "Twitter Web App", "created_at": "2022-12-08T05:15:41.000Z", "edit_history_tweet_ids": ["1600720749224136704"], "author_id": "2170278304", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533262098927617"}], "id": "1600720749224136704", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "Great thread on the 2014 IMWG criteria. Several points in this brief thread are often misunderstood. I want to highlight two tweets, but the entire thread is gold. https://t.co/q1x3bbqou2", "source": "Twitter Web App", "entities": {"annotations": [{"start": 25, "end": 28, "probability": 0.7437, "type": "Other", "normalized_text": "IMWG"}], "urls": [{"start": 164, "end": 187, "url": "https://t.co/q1x3bbqou2", "expanded_url": "https://twitter.com/VincentRK/status/1600533243392057344", "display_url": "twitter.com/VincentRK/stat\u2026"}]}, "created_at": "2022-12-07T19:11:56.000Z", "edit_history_tweet_ids": ["1600568812025298961"], "author_id": "4051359136", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600533243392057344"}], "id": "1600568812025298961", "conversation_id": "1600568812025298961"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 15, "end": 29, "username": "CyclingDoctor", "id": "23036480"}, {"start": 30, "end": 42, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 43, "end": 55, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 56, "end": 71, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 72, "end": 81, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 82, "end": 96, "username": "DavidSteensma", "id": "2739065578"}, {"start": 97, "end": 107, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 108, "end": 121, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 122, "end": 132, "username": "myelomaMD", "id": "301568235"}, {"start": 133, "end": 142, "username": "Geoff_Uy", "id": "985139345928736768"}], "annotations": [{"start": 216, "end": 222, "probability": 0.6069, "type": "Other", "normalized_text": "myeloma"}]}, "text": "@MichaelJSlade @CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @ManniMD1 @DavidSteensma @bdermanmd @VPrasadMDMPH @myelomaMD @Geoff_Uy I usually apply the oral session filter and the field I\u2019m interested in (myeloma) and quickly scan through the abstracts, printing ones I feel are important for me. The exercise then of picking my top 5 each year ensures I read the ones I print (about ~25) closely.", "source": "Twitter for iPhone", "created_at": "2022-12-08T02:08:54.000Z", "edit_history_tweet_ids": ["1600673744728489984"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600642889280798721"}], "id": "1600673744728489984", "in_reply_to_user_id": "626650397", "conversation_id": "1600642889280798721"}, {"entities": {"mentions": [{"start": 141, "end": 155, "username": "CyclingDoctor", "id": "23036480"}, {"start": 156, "end": 168, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 169, "end": 181, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 182, "end": 197, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 198, "end": 207, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 208, "end": 222, "username": "DavidSteensma", "id": "2739065578"}, {"start": 223, "end": 233, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 234, "end": 247, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 248, "end": 258, "username": "VincentRK", "id": "24261916"}, {"start": 259, "end": 269, "username": "myelomaMD", "id": "301568235"}, {"start": 270, "end": 279, "username": "Geoff_Uy", "id": "985139345928736768"}], "annotations": [{"start": 63, "end": 69, "probability": 0.6243, "type": "Other", "normalized_text": "ASH2022"}], "hashtags": [{"start": 62, "end": 70, "tag": "ASH2022"}]}, "text": "As a trainee who\u2019s overwhelmed by the volume of abstracts for #ASH2022, any advice on filtering/reviewing/scheduling from the senior folks?\n\n@CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @ManniMD1 @DavidSteensma @bdermanmd @VPrasadMDMPH @VincentRK @myelomaMD @Geoff_Uy", "source": "Twitter for iPhone", "created_at": "2022-12-08T00:06:17.000Z", "edit_history_tweet_ids": ["1600642889280798721"], "author_id": "626650397", "lang": "en", "id": "1600642889280798721", "conversation_id": "1600642889280798721"}, {"text": "This thread \ud83d\udc47\ud83c\udffd #ASH22, a testament to the collaborative nature of the #mmsm community. https://t.co/FZK1jDmJvj", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 16, "end": 20, "probability": 0.6979, "type": "Other", "normalized_text": "ASH22"}, {"start": 71, "end": 74, "probability": 0.5962, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 87, "end": 110, "url": "https://t.co/FZK1jDmJvj", "expanded_url": "https://twitter.com/VincentRK/status/1600533243392057344", "display_url": "twitter.com/VincentRK/stat\u2026"}], "hashtags": [{"start": 15, "end": 21, "tag": "ASH22"}, {"start": 70, "end": 75, "tag": "mmsm"}]}, "created_at": "2022-12-07T18:16:56.000Z", "edit_history_tweet_ids": ["1600554971971436574"], "author_id": "83911786", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600533243392057344"}], "id": "1600554971971436574", "conversation_id": "1600554971971436574"}, {"text": "Insulin users: we are evaluating a future insulin test program and would like your feedback.\n\nIf we offered a 90-day supply of a fast-acting insulin (up to 12 vials/8 packs of pens) for $170 incl. shipping, what would you think?\n\nShare you feedback here: https://t.co/F2BNPLOOtn https://t.co/O5JPTMsE45", "source": "Twitter Web App", "entities": {"urls": [{"start": 255, "end": 278, "url": "https://t.co/F2BNPLOOtn", "expanded_url": "http://bit.ly/insulintestfeedback", "display_url": "bit.ly/insulintestfee\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1601406015508914176/owbEu9fX?format=png&name=orig", "width": 256, "height": 192}, {"url": "https://pbs.twimg.com/news_img/1601406015508914176/owbEu9fX?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Fill | Insulin Test Feedback", "description": "This form is intended for insulin users only.\u00a0 We are evaluating a test program for insulin and would like feedback from insulin users. For this test, we would make a 90-day supply of a fast-acting insulin available for $170.00, up to 12 vials or 8 packs of pens. The insulin would be shipped directly to your home.", "unwound_url": "https://forms.office.com/Pages/ResponsePage.aspx?id=nlWlyavTPES7xglhq5HvDwx1m5bO2mRDq1ekDvUshMtUNUZBM0dDUTA3RVpUOEY1WVNWVDE4U0JTMiQlQCN0PWcu"}, {"start": 279, "end": 302, "url": "https://t.co/O5JPTMsE45", "expanded_url": "https://twitter.com/costplusdrugs/status/1600518796665569282/photo/1", "display_url": "pic.twitter.com/O5JPTMsE45", "media_key": "3_1600518651693731841"}]}, "created_at": "2022-12-07T15:53:11.000Z", "edit_history_tweet_ids": ["1600518796665569282"], "author_id": "1284331089977151488", "lang": "en", "id": "1600518796665569282", "conversation_id": "1600518796665569282"}, {"entities": {"mentions": [{"start": 143, "end": 155, "username": "thanosdimop", "id": "3419708038"}, {"start": 156, "end": 165, "username": "mvmateos", "id": "2239926566"}, {"start": 166, "end": 176, "username": "myelomaMD", "id": "301568235"}, {"start": 177, "end": 190, "username": "BrianDurieMD", "id": "339306345"}, {"start": 191, "end": 205, "username": "SagarLonialMD", "id": "2289851689"}, {"start": 206, "end": 215, "username": "szusmani", "id": "83911786"}, {"start": 216, "end": 229, "username": "ADispenzieri", "id": "2172483547"}, {"start": 230, "end": 244, "username": "sykristinsson", "id": "3078258341"}, {"start": 245, "end": 259, "username": "DrOlaLandgren", "id": "2257190339"}, {"start": 260, "end": 270, "username": "mbeksac56", "id": "2171123355"}, {"start": 271, "end": 287, "username": "BrunoPaiva_UNAV", "id": "1335161063382376448"}], "annotations": [{"start": 39, "end": 42, "probability": 0.3832, "type": "Other", "normalized_text": "IMWG"}, {"start": 61, "end": 76, "probability": 0.541, "type": "Person", "normalized_text": "Jesus San Miguel"}, {"start": 79, "end": 95, "probability": 0.5077, "type": "Other", "normalized_text": "Giampaolo Merlini"}, {"start": 98, "end": 109, "probability": 0.9166, "type": "Person", "normalized_text": "Ken Anderson"}, {"start": 112, "end": 119, "probability": 0.8737, "type": "Person", "normalized_text": "Bob Kyle"}, {"start": 134, "end": 140, "probability": 0.8614, "type": "Other", "normalized_text": "Twitter"}], "urls": [{"start": 288, "end": 311, "url": "https://t.co/dmqkEouveg", "expanded_url": "https://twitter.com/VincentRK/status/1600533278792073219/photo/1", "display_url": "pic.twitter.com/dmqkEouveg", "media_key": "3_1600533275109376000"}]}, "text": "12/ This is all thanks &amp; credit to IMWG &amp; coauthors. Jesus San Miguel, Giampaolo Merlini, Ken Anderson, Bob Kyle. Many are on Twitter: @thanosdimop @mvmateos @myelomaMD @BrianDurieMD @SagarLonialMD @szusmani @ADispenzieri @sykristinsson @DrOlaLandgren @mbeksac56 @BrunoPaiva_UNAV https://t.co/dmqkEouveg", "source": "Twitter for iPhone", "created_at": "2022-12-07T16:50:44.000Z", "edit_history_tweet_ids": ["1600533278792073219"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533273658068993"}], "id": "1600533278792073219", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "11/ There\u2019s a lot more in this paper. The authors worked on many drafts to ensure we got it right and had consensus. \n\nI have never worked on a paper where every single sentence has so much importance and meaning as in this paper.", "source": "Twitter for iPhone", "created_at": "2022-12-07T16:50:43.000Z", "edit_history_tweet_ids": ["1600533273658068993"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533271296753665"}], "id": "1600533273658068993", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "10/ CRAB features do not need to be symptomatic.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 4, "end": 7, "probability": 0.686, "type": "Other", "normalized_text": "CRAB"}]}, "created_at": "2022-12-07T16:50:43.000Z", "edit_history_tweet_ids": ["1600533271296753665"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533269208043524"}], "id": "1600533271296753665", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "9/ Infections, suppression of uninvolved immunoglobulins are not considered myeloma defining events. Too non specific. Patients must meet one of the 7 myeloma defining events defined in the criteria to be considered as having myeloma.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 151, "end": 157, "probability": 0.5329, "type": "Other", "normalized_text": "myeloma"}]}, "created_at": "2022-12-07T16:50:42.000Z", "edit_history_tweet_ids": ["1600533269208043524"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533267152789504"}], "id": "1600533269208043524", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "8/ Presence of clonal plasma cells in the bone marrow biopsy is not needed for diagnosis of myeloma. Presence of a biopsy proven plasmacytoma with another myeloma defining event is sufficient.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 15, "end": 27, "probability": 0.5625, "type": "Other", "normalized_text": "clonal plasma"}, {"start": 54, "end": 59, "probability": 0.6269, "type": "Other", "normalized_text": "biopsy"}, {"start": 92, "end": 98, "probability": 0.7516, "type": "Other", "normalized_text": "myeloma"}, {"start": 129, "end": 140, "probability": 0.7141, "type": "Other", "normalized_text": "plasmacytoma"}, {"start": 155, "end": 161, "probability": 0.6979, "type": "Other", "normalized_text": "myeloma"}]}, "created_at": "2022-12-07T16:50:42.000Z", "edit_history_tweet_ids": ["1600533267152789504"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533265529438209"}], "id": "1600533267152789504", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "7/ Presence of serum or urine M protein is not necessary for myeloma diagnosis. Non secretory myeloma is myeloma and treated as such. It\u2019s not a separate disease. It\u2019s more of a description, and it\u2019s understood that monitoring will be different in such patients.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 32, "end": 38, "probability": 0.4887, "type": "Other", "normalized_text": "protein"}, {"start": 61, "end": 67, "probability": 0.7069, "type": "Other", "normalized_text": "myeloma"}, {"start": 105, "end": 111, "probability": 0.5199, "type": "Other", "normalized_text": "myeloma"}]}, "created_at": "2022-12-07T16:50:41.000Z", "edit_history_tweet_ids": ["1600533265529438209"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533263629557763"}], "id": "1600533265529438209", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "6/ Only light chain cast nephropathy qualifies as a myeloma defining renal event. All other renal lesions attributable to monoclonal protein are considered unique disorders and do not automatically mean malignancy or meet the criteria for myeloma diagnosis.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 25, "end": 35, "probability": 0.8197, "type": "Other", "normalized_text": "nephropathy"}, {"start": 52, "end": 58, "probability": 0.6255, "type": "Other", "normalized_text": "myeloma"}, {"start": 122, "end": 131, "probability": 0.5397, "type": "Other", "normalized_text": "monoclonal"}, {"start": 239, "end": 245, "probability": 0.7854, "type": "Other", "normalized_text": "myeloma"}]}, "created_at": "2022-12-07T16:50:41.000Z", "edit_history_tweet_ids": ["1600533263629557763"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533262098927617"}], "id": "1600533263629557763", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "5/ Clarification and recommendations for   advanced imaging (CT, PET-CT ) to detect lytic bone lesions. \n\nTo distinguish MM from SMM, MRI imaging may be needed.", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 65, "end": 68, "probability": 0.492, "type": "Other", "normalized_text": "PET-"}, {"start": 121, "end": 122, "probability": 0.5566, "type": "Other", "normalized_text": "MM"}, {"start": 129, "end": 131, "probability": 0.7194, "type": "Other", "normalized_text": "SMM"}, {"start": 134, "end": 136, "probability": 0.6508, "type": "Other", "normalized_text": "MRI"}]}, "created_at": "2022-12-07T16:50:40.000Z", "edit_history_tweet_ids": ["1600533262098927617"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533259494227968"}], "id": "1600533262098927617", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "4/ MGUS was formally classified into 3 types with specific diagnostic criteria outlined for each. #ASH22 #MedTwitter https://t.co/f7Cjf06vM3", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 3, "end": 6, "probability": 0.6235, "type": "Organization", "normalized_text": "MGUS"}, {"start": 99, "end": 103, "probability": 0.6199, "type": "Other", "normalized_text": "ASH22"}, {"start": 106, "end": 115, "probability": 0.8218, "type": "Other", "normalized_text": "MedTwitter"}], "urls": [{"start": 117, "end": 140, "url": "https://t.co/f7Cjf06vM3", "expanded_url": "https://twitter.com/VincentRK/status/1600533259494227968/photo/1", "display_url": "pic.twitter.com/f7Cjf06vM3", "media_key": "3_1600533256176373761"}], "hashtags": [{"start": 98, "end": 104, "tag": "ASH22"}, {"start": 105, "end": 116, "tag": "MedTwitter"}]}, "created_at": "2022-12-07T16:50:40.000Z", "edit_history_tweet_ids": ["1600533259494227968"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533254372745220"}], "id": "1600533259494227968", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "3/ We simultaneously updated the diagnostic criteria for related plasma cell disorders including MGUS, SMM, and solitary plasmacytoma. https://t.co/D9l07jzAP6", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 97, "end": 100, "probability": 0.6413, "type": "Other", "normalized_text": "MGUS"}, {"start": 103, "end": 105, "probability": 0.8006, "type": "Other", "normalized_text": "SMM"}, {"start": 121, "end": 132, "probability": 0.6278, "type": "Other", "normalized_text": "plasmacytoma"}], "urls": [{"start": 135, "end": 158, "url": "https://t.co/D9l07jzAP6", "expanded_url": "https://twitter.com/VincentRK/status/1600533254372745220/photo/1", "display_url": "pic.twitter.com/D9l07jzAP6", "media_key": "3_1600533251898097666"}]}, "created_at": "2022-12-07T16:50:38.000Z", "edit_history_tweet_ids": ["1600533254372745220"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533249339572227"}], "id": "1600533254372745220", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"text": "2/ The paradigm shifting  change was including 3 biomarkers that were associated with 80% or greater probability of progression within 2 years as myeloma defining events on top of CRAB. \n\n&gt;100 myeloma experts gave input for the paper. #ASH22 #MedTwitter https://t.co/ZoIwF4QgOZ", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 146, "end": 152, "probability": 0.6029, "type": "Other", "normalized_text": "myeloma"}, {"start": 180, "end": 183, "probability": 0.6512, "type": "Other", "normalized_text": "CRAB"}, {"start": 196, "end": 202, "probability": 0.4858, "type": "Other", "normalized_text": "myeloma"}, {"start": 239, "end": 243, "probability": 0.5844, "type": "Other", "normalized_text": "ASH22"}, {"start": 246, "end": 255, "probability": 0.8445, "type": "Other", "normalized_text": "MedTwitter"}], "urls": [{"start": 257, "end": 280, "url": "https://t.co/ZoIwF4QgOZ", "expanded_url": "https://twitter.com/VincentRK/status/1600533249339572227/photo/1", "display_url": "pic.twitter.com/ZoIwF4QgOZ", "media_key": "3_1600533245560487936"}], "hashtags": [{"start": 238, "end": 244, "tag": "ASH22"}, {"start": 245, "end": 256, "tag": "MedTwitter"}]}, "created_at": "2022-12-07T16:50:37.000Z", "edit_history_tweet_ids": ["1600533249339572227"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600533243392057344"}], "id": "1600533249339572227", "in_reply_to_user_id": "24261916", "conversation_id": "1600533243392057344"}, {"entities": {"mentions": [{"start": 149, "end": 164, "username": "TheLancetOncol", "id": "50265238"}], "annotations": [{"start": 18, "end": 22, "probability": 0.6619, "type": "Other", "normalized_text": "ASH22"}, {"start": 29, "end": 32, "probability": 0.6619, "type": "Other", "normalized_text": "IMWG"}, {"start": 166, "end": 175, "probability": 0.8809, "type": "Other", "normalized_text": "MedTwitter"}, {"start": 244, "end": 247, "probability": 0.6294, "type": "Other", "normalized_text": "IMWG"}], "urls": [{"start": 177, "end": 200, "url": "https://t.co/61ohPFLtGi", "expanded_url": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70442-5/fulltext", "display_url": "thelancet.com/journals/lanon\u2026", "status": 200, "title": "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma", "description": "This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identification of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients.", "unwound_url": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70442-5/fulltext"}], "hashtags": [{"start": 17, "end": 23, "tag": "ASH22"}, {"start": 165, "end": 176, "tag": "MedTwitter"}]}, "text": "Just in time for #ASH22\n\nThe IMWG updated diagnostic criteria for myeloma &amp; related disorders has just become the most cited myeloma paper ever. @TheLancetOncol #MedTwitter https://t.co/61ohPFLtGi\n\nI was honored to lead this effort for the IMWG. A thread on the main changes. \n1/", "source": "Twitter for iPhone", "created_at": "2022-12-07T16:50:36.000Z", "edit_history_tweet_ids": ["1600533243392057344"], "author_id": "24261916", "lang": "en", "id": "1600533243392057344", "conversation_id": "1600533243392057344"}, {"entities": {"mentions": [{"start": 136, "end": 144, "username": "mtmdphd", "id": "190337035"}, {"start": 145, "end": 156, "username": "Mohty_EBMT", "id": "2626263112"}], "annotations": [{"start": 158, "end": 167, "probability": 0.9279, "type": "Other", "normalized_text": "MedTwitter"}], "urls": [{"start": 169, "end": 192, "url": "https://t.co/ViJGEFUBTH", "expanded_url": "https://twitter.com/VincentRK/status/1599840937622265856/photo/1", "display_url": "pic.twitter.com/ViJGEFUBTH", "media_key": "3_1599840932387512320"}], "hashtags": [{"start": 157, "end": 168, "tag": "MedTwitter"}]}, "text": "It\u2019s a complicated landscape and I have tried to make it simple for practicing clinicians. \n\nThere are changes compared to prior years. @mtmdphd @Mohty_EBMT #MedTwitter https://t.co/ViJGEFUBTH", "source": "Twitter for iPhone", "created_at": "2022-12-05T18:59:37.000Z", "edit_history_tweet_ids": ["1599840937622265856"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599839923275591682"}], "id": "1599840937622265856", "in_reply_to_user_id": "24261916", "conversation_id": "1599838360419213312"}, {"text": "Very grateful to have received my flu shot in mid-October.\n\nMake sure to get yours! https://t.co/zGnVfgzN0e", "source": "Twitter for Android", "entities": {"urls": [{"start": 84, "end": 107, "url": "https://t.co/zGnVfgzN0e", "expanded_url": "https://twitter.com/VincentRK/status/1600237131183448064", "display_url": "twitter.com/VincentRK/stat\u2026"}]}, "created_at": "2022-12-06T21:17:16.000Z", "edit_history_tweet_ids": ["1600237966147825664"], "author_id": "2297835854", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600237131183448064"}], "id": "1600237966147825664", "conversation_id": "1600237966147825664"}, {"text": "Vulnerable patients who are already suffering from their illness should not have the added problem of fighting with insurance companies for coverage. Reform is needed.", "source": "Twitter for iPhone", "created_at": "2022-12-06T20:32:35.000Z", "edit_history_tweet_ids": ["1600226720157605888"], "author_id": "24261916", "lang": "en", "id": "1600226720157605888", "conversation_id": "1600226720157605888"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}]}, "text": "@VincentRK Our Doctors should not have to fight with them either.", "source": "Twitter for iPhone", "created_at": "2022-12-06T20:39:15.000Z", "edit_history_tweet_ids": ["1600228397799510016"], "author_id": "1011728551647817729", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600226720157605888"}], "id": "1600228397799510016", "in_reply_to_user_id": "24261916", "conversation_id": "1600226720157605888"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 80, "end": 83, "probability": 0.4124, "type": "Other", "normalized_text": "Mayo"}, {"start": 131, "end": 133, "probability": 0.5573, "type": "Other", "normalized_text": "SMM"}, {"start": 147, "end": 149, "probability": 0.6911, "type": "Other", "normalized_text": "Len"}, {"start": 154, "end": 160, "probability": 0.6873, "type": "Other", "normalized_text": "Len dex"}]}, "text": "@VincentRK Sounds good! Thanks for explaining this! So my assumption is that at Mayo clinic, it is standard practice to treat HR - SMM with either Len or Len dex. Observation is rarely an option in your practice (if at all offered). Is that correct?", "source": "Twitter for Android", "created_at": "2022-12-06T20:19:39.000Z", "edit_history_tweet_ids": ["1600223465935867904"], "author_id": "1365049914674266116", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600220835490320384"}], "id": "1600223465935867904", "in_reply_to_user_id": "24261916", "conversation_id": "1599838360419213312"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "DrTJM_MD", "id": "1365049914674266116"}], "annotations": [{"start": 23, "end": 26, "probability": 0.4687, "type": "Other", "normalized_text": "RCTs"}, {"start": 31, "end": 33, "probability": 0.6297, "type": "Other", "normalized_text": "Obs"}, {"start": 38, "end": 40, "probability": 0.4998, "type": "Other", "normalized_text": "Len"}, {"start": 46, "end": 48, "probability": 0.5277, "type": "Other", "normalized_text": "Len"}, {"start": 50, "end": 52, "probability": 0.5288, "type": "Other", "normalized_text": "Dex"}, {"start": 59, "end": 61, "probability": 0.4254, "type": "Other", "normalized_text": "obs"}, {"start": 66, "end": 69, "probability": 0.4447, "type": "Person", "normalized_text": "Dara"}, {"start": 153, "end": 156, "probability": 0.447, "type": "Other", "normalized_text": "RCTs"}, {"start": 172, "end": 173, "probability": 0.5777, "type": "Other", "normalized_text": "Rd"}, {"start": 178, "end": 180, "probability": 0.5686, "type": "Other", "normalized_text": "DRd"}, {"start": 187, "end": 188, "probability": 0.5613, "type": "Other", "normalized_text": "Rd"}, {"start": 193, "end": 197, "probability": 0.5679, "type": "Other", "normalized_text": "IsaRd"}, {"start": 233, "end": 235, "probability": 0.4506, "type": "Other", "normalized_text": "SMM"}]}, "text": "@DrTJM_MD We have done RCTs of Obs vs Len and Len/Dex. And obs vs Dara (results not available). \n\nThe hypothesis is triplet will be superior. That\u2019s why RCTs are going on. Rd vs DRd; and Rd vs IsaRd. \n\nWe don\u2019t recommend treating HR SMM indefinitely. It\u2019s 2 years and stop.", "source": "Twitter for iPhone", "created_at": "2022-12-06T20:09:12.000Z", "edit_history_tweet_ids": ["1600220835490320384"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600194954738905088"}], "id": "1600220835490320384", "in_reply_to_user_id": "1365049914674266116", "conversation_id": "1599838360419213312"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 36, "end": 38, "probability": 0.5296, "type": "Other", "normalized_text": "SMM"}, {"start": 60, "end": 62, "probability": 0.7336, "type": "Other", "normalized_text": "RVD"}, {"start": 224, "end": 235, "probability": 0.6119, "type": "Other", "normalized_text": "asymptomatic"}]}, "text": "@VincentRK If we want to treat HR - SMM, why not treat with RVD? I'd think since one will be on treatment until death (most of them), I would rather want pts maximum time off any treatment as long as possible, especially if asymptomatic. Don't you think there should be a obs arm as well?", "source": "Twitter for Android", "created_at": "2022-12-06T18:26:22.000Z", "edit_history_tweet_ids": ["1600194954738905088"], "author_id": "1365049914674266116", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599838360419213312"}], "id": "1600194954738905088", "in_reply_to_user_id": "24261916", "conversation_id": "1599838360419213312"}, {"entities": {"mentions": [{"start": 74, "end": 89, "username": "MDAndersonNews", "id": "14062554"}, {"start": 111, "end": 124, "username": "DianeBodurka", "id": "938869906531110915"}], "annotations": [{"start": 245, "end": 249, "probability": 0.3988, "type": "Other", "normalized_text": "BPDCN"}], "urls": [{"start": 267, "end": 290, "url": "https://t.co/puOBD621Kj", "expanded_url": "https://twitter.com/doctorpemm/status/1600183100629131264/photo/1", "display_url": "pic.twitter.com/puOBD621Kj", "media_key": "3_1600183094417440768"}, {"start": 267, "end": 290, "url": "https://t.co/puOBD621Kj", "expanded_url": "https://twitter.com/doctorpemm/status/1600183100629131264/photo/1", "display_url": "pic.twitter.com/puOBD621Kj", "media_key": "3_1600183094409105411"}], "hashtags": [{"start": 219, "end": 229, "tag": "endcancer"}, {"start": 230, "end": 236, "tag": "leusm"}, {"start": 237, "end": 243, "tag": "MPNSM"}, {"start": 244, "end": 250, "tag": "BPDCN"}, {"start": 251, "end": 263, "tag": "RareDisease"}]}, "text": "\ud83d\udc49\ud83d\udc49\ud83d\udc49Deeply honored to be recognized today as a Faculty Educator Awardee by @MDAndersonNews !!!! Special\ud83d\ude4f\ud83c\udffe to Dr @DianeBodurka , Dr Chambers &amp; the Faculty Education Committee as well as my own mentors and nominators! #endcancer #leusm #MPNSM #BPDCN #RareDisease \ud83d\udc4f\ud83c\udffd https://t.co/puOBD621Kj", "source": "Twitter for iPhone", "created_at": "2022-12-06T17:39:15.000Z", "edit_history_tweet_ids": ["1600183100629131264"], "author_id": "2429552622", "lang": "en", "id": "1600183100629131264", "conversation_id": "1600183100629131264"}, {"entities": {"mentions": [{"start": 45, "end": 55, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 36, "end": 42, "probability": 0.7152, "type": "Other", "normalized_text": "myeloma"}, {"start": 57, "end": 63, "probability": 0.6368, "type": "Other", "normalized_text": "myeloma"}, {"start": 89, "end": 98, "probability": 0.4963, "type": "Other", "normalized_text": "MedTwitter"}], "urls": [{"start": 199, "end": 222, "url": "https://t.co/3IjdNk06um", "expanded_url": "https://twitter.com/imedverse/status/1600086917919698944/photo/1", "display_url": "pic.twitter.com/3IjdNk06um", "media_key": "3_1600086907551354880"}, {"start": 199, "end": 222, "url": "https://t.co/3IjdNk06um", "expanded_url": "https://twitter.com/imedverse/status/1600086917919698944/photo/1", "display_url": "pic.twitter.com/3IjdNk06um", "media_key": "3_1600086907547193344"}, {"start": 199, "end": 222, "url": "https://t.co/3IjdNk06um", "expanded_url": "https://twitter.com/imedverse/status/1600086917919698944/photo/1", "display_url": "pic.twitter.com/3IjdNk06um", "media_key": "3_1600086907584942080"}, {"start": 199, "end": 222, "url": "https://t.co/3IjdNk06um", "expanded_url": "https://twitter.com/imedverse/status/1600086917919698944/photo/1", "display_url": "pic.twitter.com/3IjdNk06um", "media_key": "3_1600086907576537090"}], "hashtags": [{"start": 56, "end": 64, "tag": "myeloma"}, {"start": 65, "end": 80, "tag": "TipsForNewDocs"}, {"start": 81, "end": 87, "tag": "MedEd"}, {"start": 88, "end": 99, "tag": "MedTwitter"}, {"start": 100, "end": 109, "tag": "medicine"}, {"start": 110, "end": 118, "tag": "medical"}, {"start": 119, "end": 128, "tag": "medicare"}, {"start": 129, "end": 136, "tag": "health"}, {"start": 137, "end": 148, "tag": "healthcare"}, {"start": 149, "end": 156, "tag": "FOAMed"}, {"start": 157, "end": 171, "tag": "ClinicalPearl"}, {"start": 172, "end": 185, "tag": "clinicaltips"}, {"start": 186, "end": 198, "tag": "MedStudents"}]}, "text": "algorithms for current treatment of myeloma\n\n@VincentRK #myeloma #TipsForNewDocs #MedEd #MedTwitter #medicine #medical #medicare #health #healthcare #FOAMed #ClinicalPearl #clinicaltips #MedStudents https://t.co/3IjdNk06um", "source": "Twitter for iPhone", "created_at": "2022-12-06T11:17:04.000Z", "edit_history_tweet_ids": ["1600086917919698944"], "author_id": "1886086740", "lang": "en", "id": "1600086917919698944", "conversation_id": "1600086917919698944"}, {"entities": {"mentions": [{"start": 59, "end": 69, "username": "VincentRK", "id": "24261916"}, {"start": 96, "end": 107, "username": "IMFmyeloma", "id": "34340707"}], "annotations": [{"start": 29, "end": 32, "probability": 0.505, "type": "Other", "normalized_text": "NDMM"}, {"start": 71, "end": 75, "probability": 0.5772, "type": "Other", "normalized_text": "ASH22"}, {"start": 78, "end": 85, "probability": 0.6908, "type": "Other", "normalized_text": "IMFASH22"}, {"start": 88, "end": 94, "probability": 0.73, "type": "Other", "normalized_text": "myeloma"}], "urls": [{"start": 108, "end": 131, "url": "https://t.co/D4EiCYWgkq", "expanded_url": "https://twitter.com/VincentRK/status/1599838360419213312", "display_url": "twitter.com/VincentRK/stat\u2026"}], "hashtags": [{"start": 28, "end": 33, "tag": "NDMM"}, {"start": 70, "end": 76, "tag": "ASH22"}, {"start": 77, "end": 86, "tag": "IMFASH22"}, {"start": 87, "end": 95, "tag": "myeloma"}]}, "text": "So important for those with #NDMM. Retweeting and thanking @VincentRK #ASH22 #IMFASH22 #myeloma @IMFmyeloma https://t.co/D4EiCYWgkq", "source": "Twitter for iPhone", "created_at": "2022-12-06T12:42:10.000Z", "edit_history_tweet_ids": ["1600108333867929600"], "author_id": "987194570", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1599838360419213312"}], "id": "1600108333867929600", "conversation_id": "1600108333867929600"}, {"entities": {"mentions": [{"start": 46, "end": 56, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 6, "end": 13, "probability": 0.6447, "type": "Other", "normalized_text": "IMFASH22"}, {"start": 58, "end": 62, "probability": 0.3816, "type": "Other", "normalized_text": "ASH22"}, {"start": 65, "end": 71, "probability": 0.6298, "type": "Other", "normalized_text": "myeloma"}, {"start": 74, "end": 77, "probability": 0.3838, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 79, "end": 102, "url": "https://t.co/Q24n65aeH8", "expanded_url": "https://twitter.com/VincentRK/status/1599838360419213312", "display_url": "twitter.com/VincentRK/stat\u2026"}], "hashtags": [{"start": 5, "end": 14, "tag": "IMFASH22"}, {"start": 57, "end": 63, "tag": "ASH22"}, {"start": 64, "end": 72, "tag": "myeloma"}, {"start": 73, "end": 78, "tag": "mmsm"}]}, "text": "Attn #IMFASH22 Support Group Leader Team from @VincentRK #ASH22 #myeloma #mmsm https://t.co/Q24n65aeH8", "source": "Twitter Web App", "created_at": "2022-12-06T00:37:19.000Z", "edit_history_tweet_ids": ["1599925919828910081"], "author_id": "987194570", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1599838360419213312"}], "id": "1599925919828910081", "conversation_id": "1599925919828910081"}, {"text": "What we did to mitigate COVID absolutely crushed flu. And there are, for real, people with medical and scientific training who think that's a bad thing.", "source": "Twitter for Android", "entities": {"annotations": [{"start": 24, "end": 28, "probability": 0.9845, "type": "Other", "normalized_text": "COVID"}]}, "created_at": "2022-12-05T01:10:11.000Z", "edit_history_tweet_ids": ["1599571804703854592"], "author_id": "151257881", "lang": "en", "id": "1599571804703854592", "conversation_id": "1599571804703854592"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}, {"start": 11, "end": 25, "username": "DrOlaLandgren", "id": "2257190339"}, {"start": 26, "end": 42, "username": "SylvesterCancer", "id": "137901227"}, {"start": 43, "end": 59, "username": "DrGarethMorgan1", "id": "1119004052476633088"}, {"start": 60, "end": 69, "username": "szusmani", "id": "83911786"}, {"start": 70, "end": 78, "username": "NBahlis", "id": "797941194944749568"}, {"start": 79, "end": 91, "username": "MoffittNews", "id": "25324110"}, {"start": 92, "end": 104, "username": "HeidelbergU", "id": "28100372"}], "annotations": [{"start": 113, "end": 119, "probability": 0.5163, "type": "Other", "normalized_text": "Vincent"}]}, "text": "@VincentRK @DrOlaLandgren @SylvesterCancer @DrGarethMorgan1 @szusmani @NBahlis @MoffittNews @HeidelbergU Thanks, Vincent! Looking forward to getting feedback, in particular on abstract 646 which we feel might be relevant for the interpretation and future design of clinical trials...", "source": "Twitter Web App", "created_at": "2022-12-05T22:07:16.000Z", "edit_history_tweet_ids": ["1599888160485699584"], "author_id": "1158556316576751617", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599882644459638784"}], "id": "1599888160485699584", "in_reply_to_user_id": "24261916", "conversation_id": "1599802164854915076"}, {"entities": {"mentions": [{"start": 109, "end": 123, "username": "DrOlaLandgren", "id": "2257190339"}, {"start": 124, "end": 140, "username": "SylvesterCancer", "id": "137901227"}, {"start": 172, "end": 188, "username": "DrGarethMorgan1", "id": "1119004052476633088"}, {"start": 189, "end": 198, "username": "szusmani", "id": "83911786"}, {"start": 213, "end": 221, "username": "NBahlis", "id": "797941194944749568"}, {"start": 223, "end": 235, "username": "MoffittNews", "id": "25324110"}, {"start": 236, "end": 248, "username": "HeidelbergU", "id": "28100372"}], "annotations": [{"start": 1, "end": 7, "probability": 0.6149, "type": "Other", "normalized_text": "ASH2022"}, {"start": 78, "end": 84, "probability": 0.6885, "type": "Other", "normalized_text": "myeloma"}, {"start": 199, "end": 210, "probability": 0.7394, "type": "Other", "normalized_text": "Maclachlan K"}], "hashtags": [{"start": 0, "end": 8, "tag": "ASH2022"}, {"start": 265, "end": 270, "tag": "mmsm"}]}, "text": "#ASH2022 is approaching and our collaborative network will present 9 orals on myeloma translational research @DrOlaLandgren @SylvesterCancer. Grateful to our collaborators @DrGarethMorgan1 @szusmani Maclachlan K. @NBahlis  @MoffittNews @HeidelbergU &amp; many more #mmsm 1/10", "source": "Twitter Web App", "created_at": "2022-12-05T16:25:33.000Z", "edit_history_tweet_ids": ["1599802164854915076"], "author_id": "1158556316576751617", "lang": "en", "id": "1599802164854915076", "conversation_id": "1599802164854915076"}, {"text": "Seeing media coverage about measles and polio outbreaks which is just sad given it\u2019s preventable\u2026\n\nBut nothing yet about the disastrous ID fellowship match. \n\nWe are definitely not ready for pandemics of future. \n\nWe not even ready for infectious diseases of the past right now!", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 40, "end": 44, "probability": 0.4853, "type": "Other", "normalized_text": "polio"}]}, "created_at": "2022-12-05T01:16:19.000Z", "edit_history_tweet_ids": ["1599573348417032199"], "author_id": "18478452", "lang": "en", "id": "1599573348417032199", "conversation_id": "1599573348417032199"}]}, "meta": {"next_token": "7140dibdnow9c7btw424ch6gr5r8v5j0128fube04pdm8", "result_count": 94, "newest_id": "1601428002617061376", "oldest_id": "1599882399533309952"}, "neighbors": ["24261916", "301568235", "83911786", "854692626015993857", "84072624", "1081903728", "262835058"]}